Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP
1:21-cv-01338
Overview
Case Number
1:21-cv-01338
Filing Date
2021-09-22
Status
Litigation filed
Court
District Court, D. Delaware
Nature of Suit
830 Patent
Parties
Defendant
Plaintiff
Court & Judges
Court
District Court, D. Delaware
Presiding Judge
Matthew F. Kennelly
Patents Involved
There are 2 patents involved in this case.
| Application Number | Patent Number | External Links |
|---|---|---|
| - | US10603314 | |
| - | US10596162 |
Docket Entries
COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against AstraZeneca AB, AstraZeneca PLC, and AstraZeneca Pharmaceuticals LP - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3704835.) - filed by Puma Biotechnology, Inc. and Wyeth LLC. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(srs) (Entered: 09/22/2021)
2021-09-22
1
COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against AstraZeneca AB, AstraZeneca PLC, and AstraZeneca Pharmaceuticals LP - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3704835.) - filed by Puma Biotechnology, Inc. and Wyeth LLC. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(srs) (Entered: 09/22/2021)
2021-09-22
2
COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against AstraZeneca AB, AstraZeneca PLC, and AstraZeneca Pharmaceuticals LP - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3704835.) - filed by Puma Biotechnology, Inc. and Wyeth LLC. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(srs) (Entered: 09/22/2021)
2021-09-22
2
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) (Entered: 09/22/2021)
2021-09-22
1
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,603,314 B2 ;10,596,162 B2. (srs) (Entered: 09/22/2021)
2021-09-22
1
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pfizer Inc. for Wyeth LLC. No Parents or Affiliates Listed for Puma Biotechnology, Inc. filed by Puma Biotechnology, Inc. and Wyeth LLC. (srs) (Entered: 09/22/2021)
2021-09-22
1
Summons Issued with Magistrate Consent Notice attached as to AstraZeneca AB on 9/22/2021; AstraZeneca PLC on 9/22/2021; AstraZeneca Pharmaceuticals LP on 9/22/2021. (srs) (Entered: 09/22/2021)
2021-09-22
1
Case Assigned/Reassigned
2021-09-29
1
No Actions
Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb)
2021-09-29
1
No Actions
MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1) - filed by AstraZeneca PLC. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 11/05/2021)
2021-11-05
1
MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1) - filed by AstraZeneca PLC. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 11/05/2021)
2021-11-05
2
OPENING BRIEF in Support re 6 MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1) filed by AstraZeneca PLC.Answering Brief/Response due date per Local Rules is 11/19/2021. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Keller, Karen) (Entered: 11/05/2021)
2021-11-05
1
OPENING BRIEF in Support re 6 MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1) filed by AstraZeneca PLC.Answering Brief/Response due date per Local Rules is 11/19/2021. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Keller, Karen) (Entered: 11/05/2021)
2021-11-05
2
OPENING BRIEF in Support re 6 MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1) filed by AstraZeneca PLC.Answering Brief/Response due date per Local Rules is 11/19/2021. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Keller, Karen) (Entered: 11/05/2021)
2021-11-05
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM and Affirmative Defenses against Puma Biotechnology, Inc., Wyeth LLC, Pfizer Inc. by AstraZeneca AB, AstraZeneca Pharmaceuticals LP.(Keller, Karen) (Entered: 11/05/2021)
2021-11-05
1
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB, AstraZeneca Pharmaceuticals LP filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Keller, Karen) (Entered: 11/05/2021)
2021-11-05
1
MOTION for Pro Hac Vice Appearance of Attorney Christopher N. Sipes, Einar Stole, Megan P. Keane, Ashley Winkler, Jason Reinecke and Melissa Keech - filed by AstraZeneca Pharmaceuticals LP. (Keller, Karen) (Entered: 11/16/2021)
2021-11-16
1
SO ORDERED
2021-11-16
1
No Actions
SO ORDERED, re 10 MOTION for Pro Hac Vice Appearance of Attorney Christopher N. Sipes, Einar Stole, Megan P. Keane, Ashley Winkler, Jason Reinecke and Melissa Keech, filed by AstraZeneca Pharmaceuticals LP. Ordered by Judge Colm F. Connolly on 11/16/2021. (kmd)
2021-11-16
1
No Actions
Pro Hac Vice Attorneys Jason Reinecke, Christopher N. Sipes, Megan P. Keane, Melissa Keech, Ashley Winkler, and Einar Stole for AstraZeneca AB, AstraZeneca PLC, and AstraZeneca Pharmaceuticals LP added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
2021-11-17
1
No Actions
Add Attorneys - PHV only
2021-11-17
1
No Actions
STIPULATION TO EXTEND TIME for Plaintiffs to respond to (1) the Counterclaims filed by AstraZeneca Pharmaceuticals LP and AstraZeneca AB (D.I. 8), and (2) the Motion to Dismiss filed by Defendant AstraZeneca PLC (D.I. 6) to December 3, 2021 - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 11/18/2021)
2021-11-18
1
SUMMONS Returned Executed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB. Pfizer Inc. served on 11/10/2021, answer due 12/1/2021. (Keller, Karen) (Entered: 11/18/2021)
2021-11-18
1
SO ORDERED, re 11 STIPULATION TO EXTEND TIME for Plaintiffs to respond to (1) the Counterclaims filed by AstraZeneca Pharmaceuticals LP and AstraZeneca AB (D.I. 8), and (2) the Motion to Dismiss filed by Defendant AstraZeneca PLC (D.I. 6) to December 3, 2021, filed by Wyeth LLC, Puma Biotechnology, Inc. Set Briefing Schedule: re 6 MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1). Answering Brief due 12/3/2021. Signed by Judge Colm F. Connolly on 11/18/2021. (kmd) (Entered: 11/18/2021)
2021-11-18
1
STIPULATION TO EXTEND TIME for Plaintiffs to respond to (1) the Counterclaims filed by AstraZeneca Pharmaceuticals LP and AstraZeneca AB (D.I. 8), and (2) the Motion to Dismiss filed by Defendant AstraZeneca PLC (D.I. 6) to December 17, 2021 - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/01/2021)
2021-12-01
1
~Util - Set Briefing Schedule - open,ans,reply,surreply AND SO ORDERED AND ~Util - Set/Reset Answer Deadline
2021-12-01
1
No Actions
~Util - Set/Reset Answer Deadline AND ~Util - Set Briefing Schedule - open,ans,reply,surreply AND SO ORDERED
2021-12-01
1
No Actions
~Util - Set Briefing Schedule - open,ans,reply,surreply AND ~Util - Set/Reset Answer Deadline AND SO ORDERED
2021-12-01
1
No Actions
SO ORDERED, re 14 STIPULATION TO EXTEND TIME for Plaintiffs to respond to (1) the Counterclaims filed by AstraZeneca Pharmaceuticals LP and AstraZeneca AB (D.I. 8), and (2) the Motion to Dismiss filed by Defendant AstraZeneca PLC (D.I. 6) to December 17, 2021, filed by Wyeth LLC, Puma Biotechnology, Inc. Reset Answer Deadlines: Puma Biotechnology, Inc. answer due 12/17/2021; Wyeth LLC answer due 12/17/2021. Re-Set Briefing Schedule: re 6 MOTION to Dismiss for Lack of Jurisdiction Over the Person and FRCP 4(k)(1). Answering Brief due 12/17/2021.Ordered by Judge Colm F. Connolly on 12/1/2021. (kmd)
2021-12-01
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Steven N. Geise, Anthony M. Insogna, Gasper J. LaRosa, Jason G. Winchester, Lisamarie LoGiudice, Meredith A. Stewart, and Shehla Wynne - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 12/02/2021)
2021-12-02
1
MOTION for Pro Hac Vice Appearance of Attorney Sara T. Horton - filed by Wyeth LLC. (Smith, Rodger) (Entered: 12/02/2021)
2021-12-02
1
SO ORDERED
2021-12-02
1
No Actions
SO ORDERED, re 15 MOTION for Pro Hac Vice Appearance of Attorney Steven N. Geise, Anthony M. Insogna, Gasper J. LaRosa, Jason G. Winchester, Lisamarie LoGiudice, Meredith A. Stewart, and Shehla Wynne, filed by Wyeth LLC, Puma Biotechnology, Inc. Ordered by Judge Colm F. Connolly on 12/2/2021. (kmd)
2021-12-02
1
No Actions
SO ORDERED, re 16 MOTION for Pro Hac Vice Appearance of Attorney Sara T. Horton, filed by Wyeth LLC. Ordered by Judge Colm F. Connolly on 12/2/2021. (kmd)
2021-12-02
1
No Actions
Order Setting Telephonic Scheduling Conference: A Scheduling Conference is set for 2/15/2022 at 09:00 AM before Judge Colm F. Connolly. If the parties have no disputes about the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 12/3/2021. (nmf) (Entered: 12/03/2021)
2021-12-03
1
STIPULATION of Dismissal without prejudice (as to Defendant AstraZeneca PLC) - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 12/10/2021)
2021-12-10
1
STIPULATION of Dismissal without prejudice (as to Counterclaim Defendant Pfizer Inc.) - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 12/10/2021)
2021-12-10
1
SO ORDERED, re 18 Stipulation of Dismissal without prejudice (as to Defendant AstraZeneca PLC), filed by Wyeth LLC, Puma Biotechnology, Inc. AstraZeneca Pharmaceuticals LP terminated. Signed by Judge Colm F. Connolly on 12/13/2021. (kmd) (Entered: 12/13/2021)
2021-12-13
1
SO ORDERED, re 19 Stipulation of Dismissal without prejudice (as to Counterclaim Defendant Pfizer Inc.), filed by Wyeth LLC, Puma Biotechnology, Inc. Pfizer Inc. terminated. Signed by Judge Colm F. Connolly on 12/13/2021. (kmd) (Entered: 12/13/2021)
2021-12-13
1
Oral Order
2021-12-16
1
No Actions
ORAL ORDER: On or before December 22, 2021, the parties shall either (1) submit to the Clerk of Court an executed Form AO 85 Notice, Consent, and Reference of a Civil Action to a Magistrate Judge, indicating their consent to have a United States Magistrate Judge conduct all proceedings in this case including trial, the entry of final judgment, and post-trial proceedings; or (2) a joint letter indicating that both parties do not consent to a reference of this action to a Magistrate Judge. The letter should not indicate which party or parties did not consent. If the parties consent, the case will be referred to Magistrate Judge Hall. Because of the Court's caseload, if the parties do not consent, the Court intends to assign the case to a visiting judge from another district. Ordered by Judge Colm F. Connolly on 12/16/2021. (nmf)
2021-12-16
1
No Actions
STIPULATION and [Proposed] Order Regarding Service of Complaint - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 12/17/2021)
2021-12-17
1
ANSWER to 8 Answer to Complaint, Counterclaim - by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 12/17/2021)
2021-12-17
1
SO ORDERED, re 22 Stipulation Regarding Service of Complaint, filed by Wyeth LLC, Puma Biotechnology, Inc. Signed by Judge Colm F. Connolly on 12/20/2021. (kmd) (Entered: 12/20/2021)
2021-12-20
1
Letter to The Honorable Colm F. Connolly from Rodger D. Smith II regarding the Court's December 16, 2021 Oral Order - re Oral Order,,,. (Smith, Rodger) (Entered: 12/22/2021)
2021-12-22
1
Oral Order
2022-01-24
1
No Actions
ORAL ORDER: The February 15, 2022 Scheduling Conference is canceled as this case will be reassigned to a visiting judge in accordance with the Court's Order of December 16, 2021. Ordered by Judge Colm F. Connolly on 1/24/2022. (nmf)
2022-01-24
1
No Actions
ORDER SETTING TELECONFERENCE, This case has been reassigned to visiting judge Matthew F. Kennelly. By February 7, 2022, the parties are to file a joint status report. The case is set for a telephonic status hearing on February 9, 2022 at 9:15 a.m. CST (10:15 a.m. EST). (See Order for further details.) Signed by Judge Matthew F Kennelly on 02/01/2022. (smg) (Entered: 02/01/2022)
2022-02-01
1
Case Assigned/Reassigned
2022-02-01
1
No Actions
Case Reassigned to Judge Matthew F Kennelly of the United States District Court for the Northern District of Illinois. Please include the initials of the Judge (MFK) after the case number on all documents filed. (rjb)
2022-02-01
1
No Actions
Joint STATUS REPORT by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 02/07/2022)
2022-02-07
1
ORAL ORDER, Telephonic status hearing held on 2/9/2022. The parties are to file a proposed scheduling order by 2/15/2022. A telephonic status hearing is set for 4/14/2022 at 8:45 a.m. CST (9:45 a.m. EST). The following call-in number will be used for the hearing: 888-684-8852, access code 746-1053. Ordered by Judge Matthew F Kennelly on 02/09/2022. (smg) (Entered: 02/09/2022)
2022-02-09
1
~Util - Set Deadlines/Hearings AND Oral Order
2022-02-09
1
No Actions
PROPOSED ORDER -- Scheduling Order -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Letter to The Honorable Matthew F. Kennelly)(Dellinger, Megan) (Entered: 02/15/2022)
2022-02-15
1
PROPOSED ORDER -- Scheduling Order -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Letter to The Honorable Matthew F. Kennelly)(Dellinger, Megan) (Entered: 02/15/2022)
2022-02-15
2
SCHEDULING ORDER: Joinder of Parties and Amendment of Pleadings due by 1/27/2023. Discovery due by 3/24/2023. Opening Expert Reports due by 5/19/2023. Rebuttal Expert Reports due by 6/30/2023. Dispositive Motions due by 11/17/2023. Claim Construction Opening Brief due by 9/2/2022. Claim Construction Answering Brief due by 10/7/2022. Claim Construction Reply Brief due by 10/28/2022. Claim Construction Surreply Brief due by 11/18/2022. Joint Claim Construction Brief due by 12/2/2022. A Markman Hearing is set for 1/20/2023 at 10:00 AM before Judge Matthew F Kennelly. Proposed Pretrial Order due by 4/9/2024. A Pretrial Conference is set for 4/30/2024 at 09:30 AM before Judge Matthew F Kennelly. A 5-day Jury Trial is set for 5/13/2024 at 09:00 AM before Judge Matthew F Kennelly. Case referred to a Magistrate Judge for the purpose of exploring ADR. Signed by Judge Matthew F Kennelly on 2/16/2022. (nmg) (Entered: 02/17/2022)
2022-02-16
1
Oral Order
2022-02-17
1
No Actions
Case Referred to Mediation - Magistrate Judge only
2022-02-17
1
No Actions
CASE REFERRED to Magistrate Judge Mary Pat Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf (Taylor, Daniel)
2022-02-17
1
No Actions
ORAL ORDER: This matter has been referred to Chief Magistrate Judge Mary Pat Thynge for ADR. Should any party (or all parties) desire to discuss mediation and its timing, the party(ies) shall contact Judge Thynge and her Law Clerk, Daniel Taylor (daniel_taylor@ded.uscourts.gov), to request that a teleconference be scheduled. Ordered by Judge Mary Pat Thynge on 2/17/2022. (Taylor, Daniel)
2022-02-17
1
No Actions
NOTICE OF SERVICE of (1) Defendants' First Set of Interrogatories (Nos. 1-11) (2) Defendants' First Set of Requests for Production (Nos. 1-94) filed by AstraZeneca AB.(Keller, Karen) (Entered: 02/25/2022)
2022-02-25
1
STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order and ESI Order to March 8, 2022 - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 02/28/2022)
2022-02-28
1
NOTICE OF SERVICE of Defendants' Initial Disclosures Pursuant to Rule 26(a)(1) filed by AstraZeneca AB, AstraZeneca PLC.(Hoeschen, Nathan) (Entered: 02/28/2022)
2022-02-28
1
NOTICE OF SERVICE of Plaintiffs' Rule 26(a) Initial Disclosures - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 03/01/2022)
2022-03-01
1
NOTICE requesting Clerk to remove Jeffrey T. Castellano as co-counsel.. (Hoeschen, Nathan) (Entered: 03/04/2022)
2022-03-04
1
PROPOSED ORDER -- [Proposed] Stipulated Protective Order -- by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 03/08/2022)
2022-03-08
1
STIPULATION TO EXTEND TIME for the parties to submit a proposed ESI Order to March 11, 2022 - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 03/08/2022)
2022-03-08
1
STIPULATION and [Proposed] Order Regarding Production of Documents and Information - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 03/11/2022)
2022-03-11
1
ORAL ORDER The parties' proposed protective order, 36, and order for production of documents and information, 38, are approved. Counsel are directed to send a Word version of each order to Judge Kennelly's proposed order e-mail address (a link to which may be found on his Northern District of Illinois website). Ordered by Judge Matthew F Kennelly on 03/11/2022. (smg) (Entered: 03/14/2022)
2022-03-14
1
~Util - Terminate Motions AND Oral Order
2022-03-14
1
No Actions
PROTECTIVE ORDER. Signed by Judge Matthew F Kennelly on 3/15/2022. (nmg) (Entered: 03/16/2022)
2022-03-16
1
STIPULATION AND ORDER Regarding Production of Documents and Information. Signed by Judge Matthew F Kennelly on 3/15/2022. (nmg) (Entered: 03/16/2022)
2022-03-16
1
NOTICE OF SERVICE of Defendants' Paragraph 3 Initial Disclosures filed by AstraZeneca AB.(Keller, Karen) (Entered: 03/18/2022)
2022-03-18
1
NOTICE OF SERVICE of (1) Plaintiffs' Disclosure of Asserted Claims and Infringement Contentions regarding U.S. Patent Nos. 10,603,314 and 10,596,162; (2) Plaintiffs' Initial Disclosures Pursuant to Paragraph 3(a)-(c) of Default Standard for Discovery; (3) Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-72); and (4) Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Main Document 43 replaced on 3/21/2022) (cna, ). (Entered: 03/21/2022)
2022-03-21
1
- CORRECTING ENTRY
2022-03-21
1
No Actions
CORRECTING ENTRY: Notice of Service at D.I. 43 has been replaced to reflect the correct date of service. (cna, )
2022-03-21
1
No Actions
NOTICE OF SERVICE of (1) Plaintiffs' Responses to Defendants' First Set of Requests for Production (Nos. 1-94); and (2) Plaintiffs' and Counterclaim Defendants' Responses and Objections to Defendants' First Set of Interrogatories (Nos. 1-11) - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 03/29/2022)
2022-03-29
1
CASE NO LONGER REFERRED to Chief Magistrate Judge Thynge for the purpose of exploring ADR. Pursuant to the Court's Standing Order No. 2022-2, dated March 14, 2022, "[u]nless otherwise directed by the Court, Magistrate Judges will no longer engage in alternative dispute resolution of patent and securities cases." See also 28 U.S.C. ยง 652(b). (Taylor, Daniel)
2022-04-04
1
No Actions
Case No Longer Referred to Mediation - Magistrate Judge only
2022-04-04
1
No Actions
CASE NO LONGER REFERRED to Chief Magistrate Judge Thynge for the purpose of exploring ADR. Pursuant to the Court's Standing Order No. 2022-2, dated March 14, 2022, "[u]nless otherwise directed by the Court, Magistrate Judges will no longer engage in alternative dispute resolution of patent and securities cases." See also 28 U.S.C. § 652(b). (Taylor, Daniel)
2022-04-04
1
No Actions
ORAL ORDER, At the Court's instance the telephonic status hearing set for 4/15/2022 is vacated and reset to 6/15/2022 at 9:00 AM ET (8:00 CT). The following call-in number will be used: 888-684-8852; access code 746-1053. On 6/8/2022 the parties are to file a joint status report detailing the progress of discovery and other pretrial proceedings in this case and reporting on any settlement discussions. Signed by Judge Matthew F Kennelly on 4/11/2022. (nmg) (Entered: 04/11/2022)
2022-04-11
1
~Util - Set Hearings AND Oral Order
2022-04-11
1
No Actions
NOTICE OF SERVICE of 1. Defendants' Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1 - 15) 2. Defendants' Responses and Objections to Plaintiffs' First Set of Requests for the Production of Documents And Things (Nos. 1 - 72) filed by AstraZeneca AB, AstraZeneca PLC.(DiBenedetto, Emily) (Entered: 04/20/2022)
2022-04-20
1
NOTICE of Change of Address for Jason G. Winchester - by Puma Biotechnology, Inc. (Smith, Rodger) (Entered: 04/29/2022)
2022-04-29
1
NOTICE OF SERVICE of AstraZeneca's Invalidity Contentions Regarding U.S. Patent Nos. 10,603,314 and 10,596,162 filed by AstraZeneca AB.(Russell, Andrew) (Entered: 05/02/2022)
2022-05-02
1
MOTION for Judgment on the Pleadings of No Pre-Issuance Damages - filed by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Proposed Order)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
1
MOTION for Judgment on the Pleadings of No Pre-Issuance Damages - filed by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Proposed Order)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
1
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
DECLARATION re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages by AstraZeneca AB, AstraZeneca PLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Keller, Karen) (Entered: 05/27/2022)
2022-05-27
2
OPENING BRIEF in Support re 49 MOTION for Judgment on the Pleadings of No Pre-Issuance Damages filed by AstraZeneca AB, AstraZeneca PLC.Answering Brief/Response due date per Local Rules is 6/10/2022. (Keller, Karen) (Entered: 05/27/2022)
2022-05-27
1
MOTION for Pro Hac Vice Appearance of Attorney Ren-How Harn - filed by Wyeth LLC. (Smith, Rodger) (Entered: 05/31/2022)
2022-05-31
1
STIPULATION TO EXTEND TIME for Plaintiffs to respond to Defendants' Motion for Judgment on the Pleadings of No Pre-Issuance Damages and for Defendants to file their Reply Brief to June 17, 2022, and July 1, 2022 - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 06/03/2022)
2022-06-03
1
Joint STATUS REPORT - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 06/08/2022)
2022-06-08
1
ORAL ORDER: At the Courts instance the telephonic status hearing set for 8:00 AM CT on 6/15/2022 is reset to 9:00 AM CT (10:00 AM ET) on that date. The following call-in number will be used: 888-684-8852; access code 746-1053. The parties should be prepared to explain to the Court the rationale for addressing now (as opposed to later in the case) the matters involved in the recently filed motion for partial judgment on the pleadings as well as whether this is a proper motion under Rule 12(c). Ordered by Judge Matthew F Kennelly on 6/14/2022. (cna, ) (Entered: 06/14/2022)
2022-06-14
1
Oral Order
2022-06-14
1
No Actions
ORAL ORDER, Telephonic status hearing held on 6/15/2022. The Court concluded that the motion for judgment on the pleadings amounts to a summary judgment motion and will determine whether to proceed with it at this time. Defendants are directed to file by 6/22/2022 a supplement to the motion that explains the rationale for addressing it at this time as opposed to later in the case at the previously-set time for filing summary judgment motions. Plaintiffs are directed to file a response to defendants submission by 6/29/2022. Telephonic hearing is set for 7/6/2022 at 8:40 a.m. CT. The following call-in number will be used: 888-684-8852; access code 746-1053. Signed by Judge Matthew F Kennelly on 6/15/2022. (apk) (Entered: 06/15/2022)
2022-06-15
1
~Util - Set Deadlines/Hearings AND Oral Order
2022-06-15
1
No Actions
RESPONSE to Order re 56 Oral Order,,, Set Deadlines/Hearings,, (Supplemental Brief in Support of Defendants' Motion for Judgment on the Pleadings of No Pre-Issuance Damages). (Russell, Andrew) (Entered: 06/22/2022)
2022-06-22
1
Add Attorneys - PHV only
2022-06-22
1
No Actions
Pro Hac Vice Attorney Shehla Wynne for Puma Biotechnology, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
2022-06-22
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Proposed Claim Terms for Construction filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 06/28/2022)
2022-06-28
1
RESPONSE to Order re 56 Oral Order,,, Set Deadlines/Hearings,, -- Plaintiffs' Response to Defendants' Supplemental Brief -- filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 06/29/2022)
2022-06-29
1
NOTICE requesting Clerk to remove Jason Reinecke as co-counsel.. (Russell, Andrew) (Entered: 07/01/2022)
2022-07-01
1
ORAL ORDER, at the Courts instance the telephonic status hearing set for today's date is vacated and reset to 7/8/2022 at 9:40 AM ET (8:40 AM CT). The following call-in number will be used: 888-684-8852; access code 746-1053. Ordered by Judge Matthew F Kennelly on 7/6/2022. (twk) (Entered: 07/06/2022)
2022-07-06
1
~Util - Set Hearings AND Oral Order
2022-07-06
1
No Actions
Telephone Conference
2022-07-08
1
No Actions
Minute Entry for proceedings held before Judge Matthew F. Kennelly - Telephonic status hearing held on 7/8/2022. Defendant's motion for judgment on the pleadings 49 is DENIED without prejudice for the reasons stated on the record. The motion may be filed as a summary judgment motion at the appropriate time. The parties are directed to file on 9/8/2022 a joint status report regarding the status of discovery and disclosures. (twk)
2022-07-08
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Proposed Claim Constructions - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 07/13/2022)
2022-07-13
1
NOTICE OF SERVICE of (1) Plaintiffs' Second Set of Interrogatories (Nos. 16-17); and (2) Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 73-75) filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 07/18/2022)
2022-07-18
1
NOTICE OF SERVICE of Defendants' Second Set of Interrogatories (No. 12) filed by AstraZeneca AB, AstraZeneca PLC.(DiBenedetto, Emily) (Entered: 07/25/2022)
2022-07-25
1
CLAIM Construction Chart by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 '314 Patent, # 2 '162 Patent, # 3 '058 Publication)(Dellinger, Megan) (Entered: 07/29/2022)
2022-07-29
1
CLAIM Construction Chart by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 '314 Patent, # 2 '162 Patent, # 3 '058 Publication)(Dellinger, Megan) (Entered: 07/29/2022)
2022-07-29
2
CLAIM Construction Chart by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 '314 Patent, # 2 '162 Patent, # 3 '058 Publication)(Dellinger, Megan) (Entered: 07/29/2022)
2022-07-29
2
CLAIM Construction Chart by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 '314 Patent, # 2 '162 Patent, # 3 '058 Publication)(Dellinger, Megan) (Entered: 07/29/2022)
2022-07-29
2
MOTION for Claim Construction re 65 Claim Construction Chart - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 07/29/2022)
2022-07-29
1
MOTION for Claim Construction [Defendants' Motion for Claim Construction] - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Russell, Andrew) (Entered: 07/29/2022)
2022-07-29
1
NOTICE OF SERVICE of 1. Defendants' Objections and Responses to Plaintiffs' Second Set of Interrogatories (Nos. 16-17) 2. Defendants' Objections and Responses to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 73-75) filed by AstraZeneca AB, AstraZeneca PLC.(Russell, Andrew) (Entered: 08/15/2022)
2022-08-15
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to AstraZeneca's Second Set of Interrogatories (No. 12) filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 08/25/2022)
2022-08-25
1
MOTION for Pro Hac Vice Appearance of Attorney Tobias Ma, Kaveh V. Saba and Priscilla Dodson - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Keller, Karen) (Entered: 08/26/2022)
2022-08-26
1
NOTICE OF SERVICE of (1) Plaintiffs' Opening Claim Construction Brief; and (2) Declaration of Jeffrey D. Winkler, Ph.D., in Support of Plaintiffs' Opening Claim Construction Brief - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 09/06/2022)
2022-09-06
1
Joint STATUS REPORT - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 09/08/2022)
2022-09-08
1
ORAL ORDER, The Court has reviewed the parties' joint status report. The motions to appear pro hac vice of Tobias Ma; Kaveh V. Saba; Priscilla Dodson; and Ren-How Harn are granted 52 70 . A telephonic status hearing is set for 12/9/2022 at 8:30 AM CT (9:30 AM ET) to discuss the claim construction hearing set for 1/20/2023. The following call-in number will be used: 888-684-8852; access code 746-1053. Ordered by Judge Matthew F Kennelly on 09/09/2022. (smg) (Entered: 09/09/2022)
2022-09-09
1
~Util - Set Hearings AND Oral Order AND ~Util - Terminate Motions
2022-09-09
1
No Actions
~Util - Set Hearings AND ~Util - Terminate Motions AND Oral Order
2022-09-09
1
No Actions
~Util - Terminate Motions AND ~Util - Set Hearings AND Oral Order
2022-09-09
1
No Actions
NOTICE OF SERVICE of Defendants' Counterclaim-Plaintiffs' Notice of Subpoena to Produce Documents, Information or Objects filed by AstraZeneca AB, AstraZeneca PLC.(DiBenedetto, Emily) (Entered: 09/22/2022)
2022-09-22
1
NOTICE OF SERVICE of Defendants' Counterclaim-Plaintiffs' Notice of Subpoena to Produce Documents, Information or Objects filed by AstraZeneca AB, AstraZeneca PLC.(DiBenedetto, Emily) (Entered: 09/28/2022)
2022-09-28
1
ORAL ORDER: The motion of defendant AstraZeneca PLC to dismiss 6 is denied as moot in light of the later dismissal without prejudice of AstraZeneca PLC (see docket numbers 18 and 20 ). Signed by Judge Matthew F Kennelly on 9/29/2022. (nmg) (Entered: 09/29/2022)
2022-09-29
1
Oral Order
2022-09-29
1
No Actions
NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief filed by AstraZeneca AB.(Russell, Andrew) (Entered: 10/10/2022)
2022-10-10
1
MOTION for Extension of Time to respond to a third party subpoena as to General Hospital Corporation (unopposed) - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (DiBenedetto, Emily) (Entered: 10/11/2022)
2022-10-11
1
ORAL ORDER, The unopposed motion for extension of time 78 is granted. The time for General Hospital Corp. to respond to the subpoena served by AstraZeneca is extended to 10/26/2022 at 9:30 AM. Signed by Judge Matthew F Kennelly on 10/12/2022. (apk) (Entered: 10/12/2022)
2022-10-12
1
Oral Order
2022-10-12
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Reply Claim Construction Brief - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 10/31/2022)
2022-10-31
1
NOTICE OF SERVICE of 1) Defendants' Sur-Reply Claim Construction Brief 2) Declaration of Melissa Keech in Support of Defendants' Sur-Reply Claim Construction Brief filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP.(Russell, Andrew) (Entered: 11/21/2022)
2022-11-21
1
JOINT CLAIM CONSTRUCTION BRIEF filed by Wyeth LLC, Puma Biotechnology, Inc.. (Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
1
APPENDIX re 82 Joint Claim Construction Brief by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-21, # 2 Declaration Of Jeffrey D. Winkler, Ph.D. with Exhibits A-L, # 3 Declaration Of Dr. Paul J. Reider with Exhibits A-I, # 4 Declaration Of Melissa Keech with Exhibits 1-3, # 5 Declaration Of Melissa Keech with Exhibit 4)(Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
1
APPENDIX re 82 Joint Claim Construction Brief by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-21, # 2 Declaration Of Jeffrey D. Winkler, Ph.D. with Exhibits A-L, # 3 Declaration Of Dr. Paul J. Reider with Exhibits A-I, # 4 Declaration Of Melissa Keech with Exhibits 1-3, # 5 Declaration Of Melissa Keech with Exhibit 4)(Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
2
APPENDIX re 82 Joint Claim Construction Brief by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-21, # 2 Declaration Of Jeffrey D. Winkler, Ph.D. with Exhibits A-L, # 3 Declaration Of Dr. Paul J. Reider with Exhibits A-I, # 4 Declaration Of Melissa Keech with Exhibits 1-3, # 5 Declaration Of Melissa Keech with Exhibit 4)(Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
2
APPENDIX re 82 Joint Claim Construction Brief by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-21, # 2 Declaration Of Jeffrey D. Winkler, Ph.D. with Exhibits A-L, # 3 Declaration Of Dr. Paul J. Reider with Exhibits A-I, # 4 Declaration Of Melissa Keech with Exhibits 1-3, # 5 Declaration Of Melissa Keech with Exhibit 4)(Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
2
APPENDIX re 82 Joint Claim Construction Brief by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-21, # 2 Declaration Of Jeffrey D. Winkler, Ph.D. with Exhibits A-L, # 3 Declaration Of Dr. Paul J. Reider with Exhibits A-I, # 4 Declaration Of Melissa Keech with Exhibits 1-3, # 5 Declaration Of Melissa Keech with Exhibit 4)(Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
2
APPENDIX re 82 Joint Claim Construction Brief by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-21, # 2 Declaration Of Jeffrey D. Winkler, Ph.D. with Exhibits A-L, # 3 Declaration Of Dr. Paul J. Reider with Exhibits A-I, # 4 Declaration Of Melissa Keech with Exhibits 1-3, # 5 Declaration Of Melissa Keech with Exhibit 4)(Dellinger, Megan) (Entered: 12/02/2022)
2022-12-02
2
CLAIM Construction Chart by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/08/2022)
2022-12-08
1
Letter to The Honorable Matthew F. Kennelly from Megan E. Dellinger regarding claim construction meet and confer - re 30 Scheduling Order,,,. (Dellinger, Megan) (Entered: 12/08/2022)
2022-12-08
1
ORAL ORDER, Telephonic status hearing held on 12/9/2022 and continued to 1/12/2023 at 8:30 a.m. CT (9:30 a.m. ET) to discuss the possible need to reset the claim construction hearing currently set for 1/20/2023. The following call-in number will be used for the hearing: 888-684-8852, access code 746-1053. Signed by Judge Matthew F Kennelly on 12/9/2022. (srs) (Entered: 12/09/2022)
2022-12-09
1
~Util - Set Deadlines/Hearings AND Oral Order
2022-12-09
1
No Actions
NOTICE OF SERVICE of Defendants' Third Set of Interrogatories (Nos. 13-15) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP.(DiBenedetto, Emily) (Entered: 12/14/2022)
2022-12-14
1
NOTICE OF SERVICE of 1. Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Jeffrey E. Settleman 2. Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Sridhar Krishna Rabindran 3. Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Raffaella Sordella 4. Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Daphne Winifred Bell 5. Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Eunice L. Kwak filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 12/27/2022)
2022-12-27
1
ORAL ORDER, Stipulation to extend time 53 is moot. Signed by Judge Matthew F Kennelly on 12/30/2022. (apk) (Entered: 12/30/2022)
2022-12-30
1
~Util - Terminate Motions AND Oral Order
2022-12-30
1
No Actions
~Util - Set Hearings AND Oral Order
2023-01-12
1
No Actions
ORAL ORDER, Telephonic status hearing held on 1/12/2023. Claim construction hearing set for 1/20/2023 is vacated and reset to 2/13/2023 at 10:00 a.m. CT (11:00 a.m. ET). The hearing will be held by video conference. The video invitation will be sent out a few days in advance of the hearing. One attorney for each party is directed to send an email address to Judge Kennelly's courtroom deputy clerk for the video invitation which may then be distributed as needed to other counsel.( A Claim Construction Hearing is set for 2/13/2023 at 11:00 AM Virtually before Judge Matthew F Kennelly.) Signed by Judge Matthew F Kennelly on 1/12/2023. (apk)
2023-01-12
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to AstraZeneca's Third Set of Interrogatories (Nos. 13-15) filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 01/23/2023)
2023-01-23
1
Official Transcript of held on 12/9/2022 before Judge Matthew F. Kennelly. Court Reporter/Transcriber Carolyn R. Cox,Email: c.cox.courtreporter@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 2/13/2023. Redacted Transcript Deadline set for 2/23/2023. Release of Transcript Restriction set for 4/24/2023. (apk) (Entered: 01/23/2023)
2023-01-23
1
Official Transcript of held on 1/12/2023 before Judge Matthew F. Kennelly. Court Reporter/Transcriber Carolyn R. Cox,Email: c.cox.courtreporter@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 2/13/2023. Redacted Transcript Deadline set for 2/23/2023. Release of Transcript Restriction set for 4/24/2023. (apk) (Entered: 01/23/2023)
2023-01-23
1
~Util - Set Hearings AND Oral Order
2023-02-02
1
No Actions
ORAL ORDER: Counsel are directed to deliver to Judge Kennelly's Chicago chambers by 2/3/2023 a USB drive(s) containing the claim construction briefs and appendices as well as any technology tutorials they have prepared. Any exhibits to a filing should be bookmarked within the PDF. A telephonic status hearing is set for 2/6/2023 at 8:30 AM Central time (9:30 AM Eastern Time) to discuss (and possibly reset) the 2/13/2023 claim construction hearing. The following call-in number will be used: 888-684-8852; access code 746-1053. ( A Status Conference is set for 2/6/2023 at 09:30 AM Telephonically before Judge Matthew F Kennelly). Signed by Judge Matthew F Kennelly on 2/2/2023. (apk)
2023-02-02
1
No Actions
NOTICE OF SERVICE of 1. Defendants' Notice of Deposition to Plaintiff Wyeth Under Fed. R. Civ. P. 30(b)(6) 2. Defendants' Notice of Deposition to Plaintiff Puma Under Fed. R. Civ. P. 30(b)(6) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 02/03/2023)
2023-02-03
1
1 - Terminate Hearings AND ~Util - Set Hearings AND Status Conference
2023-02-06
1
No Actions
1 - Terminate Hearings AND Status Conference AND ~Util - Set Hearings
2023-02-06
1
No Actions
~Util - Set Hearings AND 1 - Terminate Hearings AND Status Conference
2023-02-06
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly: Telephonic status hearing held on 2/6/2023. The claim construction hearing set for 2/13/2023 is vacated and reset to 3/17/2023 at 11:00 a.m. Central time (12:00 p.m. Eastern time). Each side will be limited to 45 minutes; the Court reserves the right to reduce each side's time allocation. The hearing will be held by video conference. Judge Kennellys courtroom deputy clerk will send out a video invitation in advance of the hearing date. (smg)
2023-02-06
1
No Actions
Official Transcript of Teleconference held on 02/06/2023 before Judge Kennelly. Court Reporter/Transcriber Carolyn Cox. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 3/2/2023. Redacted Transcript Deadline set for 3/13/2023. Release of Transcript Restriction set for 5/10/2023. (smg) (Entered: 02/09/2023)
2023-02-09
1
Joint STIPULATION and [Proposed] Order to Extend Various Deadlines by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 02/17/2023)
2023-02-17
1
NOTICE OF SERVICE of 1. Defendants' Objections and Responses to Plaintiffs' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) 2. Defendants' Amended Initial Disclosures Pursuant to Rule 26(a)(1) 3. Defendants' Second Set of Requests for Production (Nos. 95-101) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 02/17/2023)
2023-02-17
1
NOTICE to Take Deposition of Darren A. Cross on March 10, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 02/23/2023)
2023-02-23
1
NOTICE to Take Deposition of M. Raymond V. Finlay on March 10, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 02/23/2023)
2023-02-23
1
NOTICE to Take Deposition of Richard A. Ward on March 10, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 02/23/2023)
2023-02-23
1
NOTICE OF SERVICE of Notice of Deposition of Defendants Pursuant to Federal Rule of Civil Procedure 30(b)(6) filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 02/23/2023)
2023-02-23
1
NOTICE of Subpoena to Testify at a Deposition in a Civil Action as to Daphne Winifred Bell by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (DiBenedetto, Emily) (Entered: 03/02/2023)
2023-03-02
1
MOTION to Compel - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 03/08/2023)
2023-03-08
1
[SEALED] OPENING BRIEF in Support re 102 MOTION to Compel filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/22/2023. (Attachments: # 1 Exhibits 1-30)(Dellinger, Megan) (Entered: 03/08/2023)
2023-03-08
1
NOTICE OF SERVICE of AstraZeneca Pharmaceuticals LP and AstraZeneca AB's Notice of Subpoena directed to Daniel A. Haber filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/09/2023)
2023-03-09
1
ORAL ORDER, A video claim construction hearing has been set for 3/17/2023 at 11:00 AM Central time (12:00 PM Eastern time). Counsel of record have received or will receive a video invitation prior to the start of the video hearing with instructions on how to join. Members of the public will be able to call in to listen to this hearing. The call-in number is (650) 479-3207 and the call-in ID is 23005383590##. Ordered by Judge Matthew F Kennelly on 3/15/2023. (twk) (Entered: 03/15/2023)
2023-03-15
1
REDACTED VERSION of 103 Opening Brief in Support by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exs. 1-30)(Dellinger, Megan) (Entered: 03/15/2023)
2023-03-15
1
REDACTED VERSION of 103 Opening Brief in Support by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exs. 1-30)(Dellinger, Megan) (Entered: 03/15/2023)
2023-03-15
2
~Util - Set Hearings AND Oral Order
2023-03-15
1
No Actions
Oral Order AND ~Util - Set Hearings
2023-03-15
1
No Actions
NOTICE to Take Deposition of Alan Auerbach on April 13, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/17/2023)
2023-03-17
1
NOTICE to Take Deposition of Douglas Hunt on April 10, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/17/2023)
2023-03-17
1
NOTICE to Take Deposition of Jeffrey E. Settleman on April 7, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/17/2023)
2023-03-17
1
NOTICE to Take Deposition of Alvin Wong on April 6, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/17/2023)
2023-03-17
1
NOTICE OF SERVICE of Subpoena to Testify at a Deposition in a Civil Action directed to Daniel A. Haber filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/17/2023)
2023-03-17
1
NOTICE OF SERVICE of 1. Subpoena to Testify at a Deposition in a Civil Action directed to Eunice L. Kwak 2. Subpoena to Testify at a Deposition in a Civil Action directed to Sridhar Krishna Rabindran 3. Subpoena to Testify at a Deposition in a Civil Action directed to Raffaella Sordella filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/17/2023)
2023-03-17
1
NOTICE OF SERVICE of Plaintiff Puma BioTechnology, Inc.'s Objections and Responses to Defendants' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 03/17/2023)
2023-03-17
1
NOTICE OF SERVICE of Plaintiff Wyeth LLC's Objections and Responses to Defendants' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 03/17/2023)
2023-03-17
1
Oral Order
2023-03-17
1
No Actions
ORAL ORDER: Video claim construction hearing held. Claim construction is taken under advisement. The parties are to submit their slides to Judge Kennellys courtroom deputy clerk by e-mail promptly. Signed by Judge Matthew F Kennelly on 03/17/2023. (apk)
2023-03-17
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Second Set of Requests for Production (Nos. 95-101) filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 03/21/2023)
2023-03-21
1
NOTICE to Take Deposition of Serban Ghiorghui on a mutually agreed upon date before May 5, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 03/21/2023)
2023-03-21
1
NOTICE to Take Deposition of Katy Miller on a mutually agreed upon date before May 5, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 03/21/2023)
2023-03-21
1
NOTICE to Take Deposition of Pascal Soriot on a mutually agreed upon date before May 5, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 03/21/2023)
2023-03-21
1
[SEALED] ANSWERING BRIEF in Opposition re 102 MOTION to Compel Discovery filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 3/29/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24)(DiBenedetto, Emily) (Entered: 03/22/2023)
2023-03-22
1
NOTICE OF SERVICE of Subpoena to Testify at a Deposition in a Civil Action directed to The General Hospital Corporation filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 03/28/2023)
2023-03-28
1
MEMORANDUM OPINION AND ORDER, The parties are directed to file by April 7, 2023 a joint status report addressing any scheduling issues going forward and reporting on the history and current status of any settlement discussions. The Court will set a further status hearing if necessary after reviewing the joint status report. (See Order for further details). Signed by Judge Matthew F Kennelly on 3/29/2023. (twk) (Entered: 03/29/2023)
2023-03-29
1
REDACTED VERSION of 119 Answering Brief in Opposition,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 03/29/2023)
2023-03-29
1
Letter to The Honorable Matthew F. Kennelly from Andrew E. Russell regarding Defendants request to stay the deadline to disclose their intent to rely on an advice of counsel defense. (Russell, Andrew) (Entered: 03/30/2023)
2023-03-30
1
ORAL ORDER : The Court sets this case for a telephonic conference on 4/4/2023 at 8:30 AM Central time (9:30 AM Eastern time) to address plaintiffs' motion to compel 102 and the issues raised in the letter filed by defense counsel on 3/29/2023 123 . The following call-in number will be used: 888-684-8852; access code 746-1053. Ordered by Judge Matthew F Kennelly on 03/30/2023. (smg) (Entered: 03/30/2023)
2023-03-30
1
~Util - Set Hearings AND Oral Order
2023-03-30
1
No Actions
[SEALED] Letter to The Honorable Matthew F. Kennelly from Rodger D. Smith II regarding Defendants' March 30, 2023 letter - re 123 Letter. (Smith, Rodger) (Entered: 03/31/2023)
2023-03-31
1
Letter to The Honorable Matthew F. Kennelly from Andrew E. Russell regarding reply to Plaintiffs' March 31, 2023 letter. (Attachments: # 1 Exhibit A)(Russell, Andrew) (Entered: 04/03/2023)
2023-04-03
1
Letter to The Honorable Matthew F. Kennelly from Andrew E. Russell regarding reply to Plaintiffs' March 31, 2023 letter. (Attachments: # 1 Exhibit A)(Russell, Andrew) (Entered: 04/03/2023)
2023-04-03
2
ORAL ORDER, Telephonic status and motion hearing held on 4/4/2023. Oral argument heard on plaintiffs' motion to compel 102 . The motion is denied for the reasons stated more fully on the record. The Court also finds that plaintiffs have thus far adequately disclosed a claim of willful infringement. Defendants' letter request to stay the deadline for disclosure of a revised advice of counsel defense is denied; however the parties are directed to work out a revised but prompt disclosure date. Ordered by Judge Matthew F Kennelly on 4/4/2023. (twk) (Entered: 04/04/2023)
2023-04-04
1
Oral Order
2023-04-04
1
No Actions
REDACTED VERSION of 125 Letter - by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 04/05/2023)
2023-04-05
1
[SEALED] MOTION to Compel Discovery - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Russell, Andrew) (Entered: 04/05/2023)
2023-04-05
1
[SEALED] OPENING BRIEF in Support re 129 MOTION to Compel Discovery filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 4/19/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37)(Russell, Andrew) (Entered: 04/05/2023)
2023-04-05
1
NOTICE OF SERVICE of Plaintiffs Puma Biotechnology, Inc. and Wyeth LLC's First Set of Requests for Admission to Defendants AstraZeneca Pharmaceuticals LP and AstraZeneca AB (Nos. 1-68) - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 04/06/2023)
2023-04-06
1
NOTICE OF SERVICE of 1. Defendants' Fourth Set of Interrogatories (Nos. 16-18) 2. Defendants' First Set of Requests for Admissions (Nos. 1-207) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 04/06/2023)
2023-04-06
1
Joint STATUS REPORT by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 04/07/2023)
2023-04-07
1
STIPULATION and [Proposed] Order to Extend Certain Deadlines re 30 Scheduling Order,,, 95 Stipulation by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 04/07/2023)
2023-04-07
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Responses and Objections to AstraZeneca's Interrogatory Nos. 5-6 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/07/2023)
2023-04-07
1
NOTICE OF SERVICE of Defendants' First Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (No. 3) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 04/10/2023)
2023-04-10
1
NOTICE to Take Deposition of Nadia G. Godin-Heymann on May 1, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/12/2023)
2023-04-12
1
REDACTED VERSION of 130 Opening Brief in Support,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 04/12/2023)
2023-04-12
1
REDACTED VERSION of 129 MOTION to Compel Discovery by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 04/12/2023)
2023-04-12
1
NOTICE to Take Deposition of Pascal Soriot (Amended) on April 24, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/14/2023)
2023-04-14
1
NOTICE to Take Deposition of Serban Ghiorghui (Amended) on April 25, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/14/2023)
2023-04-14
1
NOTICE to Take Deposition of Darren A. Cross (Amended) on April 27, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/14/2023)
2023-04-14
1
NOTICE to Take Deposition of M. Raymond V. Finlay (Amended) on May 3, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/14/2023)
2023-04-14
1
NOTICE to Take Deposition of Richard A. Ward (Amended) on May 5, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/14/2023)
2023-04-14
1
ORAL ORDER, Defendants' motion to compel discovery 129 is set for a telephonic hearing on 5/2/2023 at 8:30 AM Central time (9:30 AM Eastern time). The following call-in number will be used: 888-684-8852; access code 746-1053. The Court reserves the right to vacate the hearing if it determines a hearing is not needed. Ordered by Judge Matthew F Kennelly on 4/17/2023. (twk) (Entered: 04/17/2023)
2023-04-17
1
Oral Order AND ~Util - Set Hearings
2023-04-17
1
No Actions
[SEALED] ANSWERING BRIEF in Opposition re 129 MOTION to Compel Discovery filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 4/26/2023. (Attachments: # 1 Exhibits 1-6)(Smith, Rodger) (Entered: 04/19/2023)
2023-04-19
1
NOTICE OF SERVICE of Defendants' Fifth Set of Interrogatories (Nos. 19-24) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 04/20/2023)
2023-04-20
1
NOTICE OF SERVICE of Subpoena to Testify at a Deposition in a Civil Action to Daniel Haber filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 04/21/2023)
2023-04-21
1
MOTION for Pro Hac Vice Appearance of Attorney Elaine Nguyen - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 04/21/2023)
2023-04-21
1
SO ORDERED, re 149 MOTION for Pro Hac Vice Appearance of Attorney Elaine Nguyen filed by AstraZeneca Pharmaceuticals, LP, AstraZeneca AB. Ordered by Judge Matthew F Kennelly on 04/24/2023. (smg) (Entered: 04/25/2023)
2023-04-24
1
SO ORDERED
2023-04-25
1
No Actions
Add Attorneys - PHV only
2023-04-25
1
No Actions
Pro Hac Vice Attorney Elaine H. Nguyen for AstraZeneca AB and AstraZeneca Pharmaceuticals, LP added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
2023-04-25
1
No Actions
[SEALED] REPLY BRIEF re 129 MOTION to Compel Discovery [Reply Brief in Support of Defendants' Motion to Compel Discovery] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1)(Russell, Andrew) (Entered: 04/26/2023)
2023-04-26
1
REDACTED VERSION of 146 Answering Brief in Opposition by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exs. 1-6)(Smith, Rodger) (Entered: 04/26/2023)
2023-04-26
1
REDACTED VERSION of 146 Answering Brief in Opposition by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exs. 1-6)(Smith, Rodger) (Entered: 04/26/2023)
2023-04-26
2
NOTICE to Take Deposition of Scott Alban on May 12, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/27/2023)
2023-04-27
1
NOTICE to Take Deposition of Jeffrey Pott on May 15, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/27/2023)
2023-04-27
1
NOTICE to Take Deposition of Benjamin McDonald on May 16, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/27/2023)
2023-04-27
1
NOTICE to Take Deposition of Christin Sullivan Miller on May 17, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/27/2023)
2023-04-27
1
[SEALED] NOTICE of Subpoenas by Puma Biotechnology, Inc., Wyeth LLC (Smith, Rodger) (Entered: 04/28/2023)
2023-04-28
1
NOTICE to Take Deposition of Robert Smith on May 11, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 04/28/2023)
2023-04-28
1
NOTICE to Take Deposition of Keith Wilner on May 5, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 04/28/2023)
2023-04-28
1
NOTICE to Take Deposition of John DeYoung on May 12, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 04/28/2023)
2023-04-28
1
NOTICE OF SERVICE of Defendants' Second Amended Initial Disclosures Pursuant to Rule 26(a)(1) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 04/28/2023)
2023-04-28
1
MOTION for Pro Hac Vice Appearance of Attorney Henry C. Thomas - filed by Wyeth LLC. (Dellinger, Megan) (Entered: 05/01/2023)
2023-05-01
1
SO ORDERED, re 162 MOTION for Pro Hac Vice Appearance of Attorney Henry C. Thomas. Ordered by Judge Matthew F Kennelly on 5/1/2023. (twk) (Entered: 05/01/2023)
2023-05-01
1
SO ORDERED
2023-05-01
1
No Actions
NOTICE to Take Deposition of Keith Wilner (Amended) on May 5, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 05/02/2023)
2023-05-02
1
NOTICE to Take Deposition of John DeYoung (Amended) on May 12, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 05/02/2023)
2023-05-02
1
NOTICE to Take Deposition of Corey Williams on May 16, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 05/02/2023)
2023-05-02
1
NOTICE to Take Deposition of Charles Zacharchuk on May 17, 2023 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 05/02/2023)
2023-05-02
1
NOTICE of Deposition Subpoena as to Darren Kassab by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (DiBenedetto, Emily) (Entered: 05/02/2023)
2023-05-02
1
Telephonic motion hearing held on 5/2/2023. Oral ruling made on the defendants motion to compel 129 . Defendants motion to compel 129 is granted in part and denied in part as more fully stated on the record. The parties are directed to file a joint status report regarding the progress of disclosures and discovery and any settlement discussions on 6/30/2023. The Court will determine after that date whether and when to set a further status hearing. (Joint Status Report due by 6/30/2023.) (apk) (Entered: 05/02/2023)
2023-05-02
1
Motion Hearing AND Order on Motion to Compel AND ~Util - Set Deadlines AND ~Util - Terminate Motions
2023-05-02
1
No Actions
REDACTED VERSION of 151 Reply Brief, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 05/03/2023)
2023-05-03
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-68) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 05/08/2023)
2023-05-08
1
NOTICE OF SERVICE of (1) Plaintiffs' Responses and Objections to Defendants' Fourth Set of Interrogatories (Nos. 16-18), and (2) Plaintiffs' Responses and Objections to Defendants' First Set of Requests for Admission (Nos. 1-207) filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 05/08/2023)
2023-05-08
1
NOTICE OF SERVICE of 1. Defendants' Second Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (No. 8) 2. Non-Party Robert A. Armitages's Objections and Responses to Subpoena Issued by Puma BioTechnology, Inc. and Wyeth LLC filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 05/09/2023)
2023-05-09
1
[SEALED] MOTION to Compel - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 05/09/2023)
2023-05-09
1
[SEALED] OPENING BRIEF in Support re 174 MOTION to Compel filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 5/23/2023. (Attachments: # 1 Exhibits 1-12, # 2 Exhibits 13-36)(Dellinger, Megan) (Entered: 05/09/2023)
2023-05-09
1
ORAL ORDER, Response to plaintiff's motion to compel is to be filed by 5/23/2023. Reply to response is to be filed by 5/30/2023. The motion is set for a telephonic hearing on 6/2/2023 at 8:30 AM Central time (9:30 AM Eastern time). The following call-in number will be used: 888-684-8852; access code 746-1053. The Court reserves the right to vacate the hearing if it determines a hearing is not needed. Ordered by Judge Matthew F Kennelly on 5/10/2023. (twk) (Entered: 05/10/2023)
2023-05-10
1
Oral Order AND ~Util - Set Hearings
2023-05-10
1
No Actions
NOTICE of Amended Subpoena as to Darren Kassab by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (DiBenedetto, Emily) (Entered: 05/15/2023)
2023-05-15
1
MOTION for Pro Hac Vice Appearance of Attorney Alexander Trzeciak - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 05/16/2023)
2023-05-16
1
REDACTED VERSION of 174 MOTION to Compel by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 05/16/2023)
2023-05-16
1
REDACTED VERSION of 175 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-12, # 2 Exhibits 13-36)(Dellinger, Megan) (Entered: 05/16/2023)
2023-05-16
1
REDACTED VERSION of 175 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-12, # 2 Exhibits 13-36)(Dellinger, Megan) (Entered: 05/16/2023)
2023-05-16
2
REDACTED VERSION of 175 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 1-12, # 2 Exhibits 13-36)(Dellinger, Megan) (Entered: 05/16/2023)
2023-05-16
2
SO ORDERED
2023-05-17
1
No Actions
Add Attorneys - PHV only
2023-05-17
1
No Actions
SO ORDERED, regarding D.I. 178 MOTION for Pro Hac Vice Appearance of Attorney Alexander Trzeciak. Signed by Judge Matthew F Kennelly on 5/17/2023. (apk)
2023-05-17
1
No Actions
Pro Hac Vice Attorney Alexander Trzeciak for AstraZeneca Pharmaceuticals, LP added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)
2023-05-17
1
No Actions
Add Attorneys - PHV only
2023-05-18
1
No Actions
Pro Hac Vice Attorney Kaveh V. Saba, Tobias Ma, and Priscilla G. Dodson for AstraZeneca Pharmaceuticals, LP, added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)
2023-05-18
1
No Actions
NOTICE OF SERVICE of (1) Plaintiffs' Supplemental Response to Defendants' Interrogatory 1; (2) Plaintiffs' Supplemental Responses to Defendants' Interrogatories 2, 3, 10, 11, 13, 14, 15, and 17; (3) Plaintiffs' Supplemental Response to Defendants' Interrogatory 4; (4) Plaintiffs' Supplemental Responses to Defendants' Interrogatories 6-7; (5) Plaintiffs' Supplemental Responses to Defendants' Interrogatories 19-24; and (6) Plaintiffs' Supplemental Disclosure of Asserted Claims and Infringement Contentions - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 05/22/2023)
2023-05-22
1
NOTICE OF SERVICE of 1. Defendants' Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-15) 2. Defendants' Supplemental Responses and Objections to Plaintiffs' Second Set of Interrogatories (Nos. 16-17) 3. Defendants' Third Amended Initial Disclosures Pursuant to Rule 26(a)(1) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 05/22/2023)
2023-05-22
1
[SEALED] ANSWERING BRIEF in Opposition re 174 MOTION to Compel [Defendants' Answering Brief in Opposition to Plaintiffs' Motion to Compel Discovery Based on Subject Matter Waiver] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 5/30/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)(DiBenedetto, Emily) (Entered: 05/23/2023)
2023-05-23
1
MOTION for Protective Order to Bar Deposition of Plaintiff Wyeth LLC's Attorney, Corey Williams - filed by Wyeth LLC. (Dellinger, Megan) (Entered: 05/24/2023)
2023-05-24
1
[SEALED] OPENING BRIEF in Support re 184 MOTION for Protective Order to Bar Deposition of Plaintiff Wyeth LLC's Attorney, Corey Williams filed by Wyeth LLC.Answering Brief/Response due date per Local Rules is 6/7/2023. (Attachments: # 1 Exhibits A-H)(Dellinger, Megan) (Entered: 05/24/2023)
2023-05-24
1
ORAL ORDER: The telephonic hearing set for 6/2/2023 is hereby vacated. Response to motion for protective order 185 is to be filed by 6/7/2023. Telephonic hearing on both this motion and the pending motion to compel is set for 6/15/2023 at 8:30 AM Central time (9:30 AM Eastern time). The following call-in number will be used: 888-684-8852; access code 746-1053. The Court reserves the right to vacate the hearing if it determines a hearing is not needed. Ordered by Judge Matthew F Kennelly on 05/25/2023. (smg) (Entered: 05/25/2023)
2023-05-25
1
1 - Terminate Deadlines and Hearings AND Oral Order AND ~Util - Set Deadlines/Hearings
2023-05-25
1
No Actions
REDACTED VERSION of 183 Answering Brief in Opposition, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 05/30/2023)
2023-05-30
1
[SEALED] REPLY BRIEF re 174 MOTION to Compel filed by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits 37-38)(Dellinger, Megan) (Entered: 05/30/2023)
2023-05-30
1
REDACTED VERSION of 185 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits A-H)(Dellinger, Megan) (Entered: 05/31/2023)
2023-05-31
1
REDACTED VERSION of 185 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibits A-H)(Dellinger, Megan) (Entered: 05/31/2023)
2023-05-31
2
MOTION for Leave to Supplement Infringement Contentions to Address Non-Public Information Learned During Fact Discovery - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 06/02/2023)
2023-06-02
1
[SEALED] OPENING BRIEF in Support re 190 MOTION for Leave to Supplement Infringement Contentions to Address Non-Public Information Learned During Fact Discovery - filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 6/16/2023. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/02/2023)
2023-06-02
1
REDACTED VERSION of 188 Reply Brief by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 06/06/2023)
2023-06-06
1
[SEALED] ANSWERING BRIEF in Opposition re 184 MOTION for Protective Order to Bar Deposition of Plaintiff Wyeth LLC's Attorney, Corey Williams filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 6/14/2023. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 D)(DiBenedetto, Emily) (Entered: 06/07/2023)
2023-06-07
1
REDACTED VERSION of 191 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/09/2023)
2023-06-09
1
REDACTED VERSION of 191 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/09/2023)
2023-06-09
2
REDACTED VERSION of 191 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/09/2023)
2023-06-09
2
REDACTED VERSION of 191 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/09/2023)
2023-06-09
2
REDACTED VERSION of 191 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/09/2023)
2023-06-09
2
REDACTED VERSION of 191 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/09/2023)
2023-06-09
2
REDACTED VERSION of 193 Answering Brief in Opposition, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/09/2023)
2023-06-09
1
MOTION for Sanctions - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(DiBenedetto, Emily) (Entered: 06/12/2023)
2023-06-12
1
MOTION for Sanctions - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(DiBenedetto, Emily) (Entered: 06/12/2023)
2023-06-12
2
[SEALED] OPENING BRIEF in Support re 196 MOTION for Sanctions filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 6/26/2023. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit)(DiBenedetto, Emily) (Entered: 06/12/2023)
2023-06-12
1
[SEALED] REPLY BRIEF re 184 MOTION for Protective Order to Bar Deposition of Plaintiff Wyeth LLC's Attorney, Corey Williams - filed by Wyeth LLC. (Dellinger, Megan) (Entered: 06/14/2023)
2023-06-14
1
[SEALED] ANSWERING BRIEF in Opposition re 190 MOTION for Leave to Supplement Infringement Contentions to Address Non-Public Information Learned During Fact Discovery filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 6/21/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(DiBenedetto, Emily) (Entered: 06/14/2023)
2023-06-14
1
ORAL ORDER, Telephonic status and motion hearing held on 6/15/2023. Oral rulings made on the motion to compel 174 and the motion for protective order 184 . Plaintiffs' motion to compel 174 is granted in part to the extent for the reasons stated on the record. Plaintiffs' motion for protective order to bar deposition of Corey Williams 184 is granted for the reasons state on the record. Signed by Judge Matthew F Kennelly on 6/15/2023. (apk) (Entered: 06/15/2023)
2023-06-15
1
MOTION for Pro Hac Vice Appearance of Attorney John C. Evans, Michelle B. Smit, Daniele San Roman, and Miguel A. Alvarez - filed by Puma Biotechnology, Inc.. (Dellinger, Megan) (Entered: 06/15/2023)
2023-06-15
1
SO ORDERED regarding D.I. 201 MOTION for Pro Hac Vice Appearance of Attorney John C. Evans, Michelle B. Smit, Daniele San Roman, and Miguel A. Alvarez. Signed by Judge Matthew F Kennelly on 6/15/2023. (apk) (Entered: 06/15/2023)
2023-06-15
1
Oral Order AND ~Util - Terminate Motions
2023-06-15
1
No Actions
SO ORDERED AND ~Util - Terminate Motions
2023-06-15
1
No Actions
Add Attorneys - PHV only
2023-06-16
1
No Actions
Pro Hac Vice Attorney Michelle B. Smit for Puma Biotechnology, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
2023-06-16
1
No Actions
REDACTED VERSION of 197 Opening Brief in Support, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/20/2023)
2023-06-20
1
REDACTED VERSION of 198 Reply Brief by Wyeth LLC. (Smith, Rodger) (Entered: 06/21/2023)
2023-06-21
1
[SEALED] REPLY BRIEF re 190 MOTION for Leave to Supplement Infringement Contentions to Address Non-Public Information Learned During Fact Discovery - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 06/21/2023)
2023-06-21
1
ORAL ORDER, The Court grants plaintiffs' motion to amend their infringement contentions 190 . Plaintiffs have made a sufficient showing of due diligence and good cause. Defendants' allegations regarding prejudice are generalized and unsupported. The Court also notes that to the extent the amendments involve contentions regarding defendants' willfulness the information needed to address the amendments is largely (and perhaps entirely) already in defendants' hands. The Court will entertain a request by defendants (if made promptly) to pursue focused and narrow fact discovery requests prompted by any changes or additions to the plaintiffs' infringement contentions. Ordered by Judge Matthew F Kennelly on 6/21/2023. (twk) (Entered: 06/21/2023)
2023-06-21
1
REDACTED VERSION of 199 Answering Brief in Opposition,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/21/2023)
2023-06-21
1
Oral Order
2023-06-21
1
No Actions
NOTICE OF SERVICE of 1. Defendants' Second Notice of Deposition to Plaintiff Puma Under Fed. R. Civ. P. 30(b)(6) (Nos. 46-48) 2.Defendants' Sixth Set of Interrogatories (No. 25) 3. Defendants' Third Set of Requests for the Production of Documents and Things (Nos. 102-104) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 06/26/2023)
2023-06-26
1
[SEALED] ANSWERING BRIEF in Opposition re 196 MOTION for Sanctions filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 7/3/2023. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7, # 8 Ex. 8, # 9 Ex. 9)(Dellinger, Megan) (Entered: 06/26/2023)
2023-06-26
1
ORAL ORDER, Telephonic hearing on motion for sanctions is set for 7/10/2023 at 8:30 AM Central Time (9:30 AM Eastern Time). The following call-in number will be used: 888-684-8852; access code 746-1053. The Court reserves the right to vacate the hearing if it determines a hearing is not needed. Ordered by Judge Matthew F Kennelly on 6/27/2023. (twk) (Entered: 06/27/2023)
2023-06-27
1
Oral Order AND ~Util - Set Hearings
2023-06-27
1
No Actions
REDACTED VERSION of 205 Reply Brief by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 06/28/2023)
2023-06-28
1
Joint STATUS REPORT by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 06/30/2023)
2023-06-30
1
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
1
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
REDACTED VERSION of 209 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 07/03/2023)
2023-07-03
2
[SEALED] REPLY BRIEF re 196 MOTION for Sanctions filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 12)(Keller, Karen) (Entered: 07/03/2023)
2023-07-03
1
STIPULATION and [Proposed] Order to Extend Certain Deadlines re 30 Scheduling Order,,, 134 Stipulation by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 07/07/2023)
2023-07-07
1
REDACTED VERSION of 214 Reply Brief by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 07/10/2023)
2023-07-10
1
NOTICE OF SERVICE of 1. Defendants' Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 8-10) 2. Defendants' Supplemental Responses and Objections to Plaintiffs' Second Set of Interrogatories (No. 16) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 07/10/2023)
2023-07-10
1
Motion Hearing AND Order on Motion for Sanctions
2023-07-10
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Telephonic motion and status hearing held on 7/10/2023. Defendant's motion for sanctions 196 is denied for the reasons stated on the record. The Court clarifies its previous orders to provide that the case is set for a jury trial on 5/13/2024 at 9:15 a.m. A joint status report discussing the progress of discovery and any settlement discussions is to be filed on 9/11/2023. (smg)
2023-07-10
1
No Actions
NOTICE to Take Deposition of Scott Alban on July 20, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 07/19/2023)
2023-07-19
1
NOTICE to Take Deposition of Pascal Soriot on August 1, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 07/19/2023)
2023-07-19
1
NOTICE to Take Deposition of Benjamin McDonald on August 3, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 07/19/2023)
2023-07-19
1
NOTICE to Take Deposition of Jeffrey Pott on August 4, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 07/19/2023)
2023-07-19
1
NOTICE to Take Deposition of Christin Sullivan Miller on August 8, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 07/19/2023)
2023-07-19
1
MOTION for Protective Order - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Hoeschen, Nathan) (Entered: 07/28/2023)
2023-07-28
1
MOTION for Protective Order - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Hoeschen, Nathan) (Entered: 07/28/2023)
2023-07-28
2
[SEALED] OPENING BRIEF in Support re 223 MOTION for Protective Order filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 8/11/2023. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S)(Hoeschen, Nathan) (Entered: 07/28/2023)
2023-07-28
1
NOTICE OF SERVICE of (1) Opening Expert Report of Alice Berger, Ph.D., (2) Opening Expert Report of Frederick H. Hausheer, M.D., (3) Expert Report of Mohan Rao, Ph.D., and (4) Opening Expert Report of Glen J. Weiss, M.D., M.B.A. - filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 07/31/2023)
2023-07-31
1
ORAL ORDER, Defendants' motion for protective order is taken under advisement. Plaintiff is directed to file a response by no later than 8/14/2023. No reply unless requested by the Court. Telephonic hearing is set for 8/18/2023 at 8:30 AM Central Time (9:30 AM Eastern Time). The following call-in number will be used: 888-684-8852; access code 746-1053. Ordered by Judge Matthew F Kennelly on 7/31/2023. (twk) (Entered: 07/31/2023)
2023-07-31
1
NOTICE OF SERVICE of 1) Opening Expert Report of Pasi A. Janne, M.D., Ph.D. 2) Opening Expert Report of Scott M. Lassman 3) Opening Expert Report of Teresa Stanek Rea 4) Opening Expert Report of Dr. Paul J. Reider 5) Opening Expert Report of Dr. Benjamin Levy 6) Opening Expert Report of David R. Taft, Ph.D. filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 07/31/2023)
2023-07-31
1
Oral Order AND ~Util - Set Hearings
2023-07-31
1
No Actions
MOTION to Enforce the Court's June 15 Order - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 08/02/2023)
2023-08-02
1
[SEALED] OPENING BRIEF in Support re 228 MOTION to Enforce the Court's June 15 Order filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 8/16/2023. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Smith, Rodger) (Entered: 08/02/2023)
2023-08-02
1
ORAL ORDER, Plaintiff's motion to enforce the June 15 order (D.I. 228 ) is taken under advisement. The default briefing schedule under the Local Rules is modified as follows. Defendants' response to the motion is to be filed by 8/10/2023. Telephonic motion hearing is set for 8/17/2023 at 8:30 AM Central Time (9:30 AM Eastern Time). The following call-in number will be used: 888-684-8852; access code 746-1053. The Court reserves the right to vacate the hearing if it determines a hearing is not needed. Signed by Judge Matthew F Kennelly on 8/3/2023. (apk) (Entered: 08/03/2023)
2023-08-03
1
1 - Terminate Deadlines AND Oral Order AND ~Util - Set Briefing Schedule - open,ans,reply,surreply AND ~Util - Set Hearings
2023-08-03
1
No Actions
REDACTED VERSION of 224 Opening Brief in Support,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 08/04/2023)
2023-08-04
1
MOTION for Pro Hac Vice Appearance of Attorney Jeffrey S. Messing - filed by Puma Biotechnology, Inc.. (Dellinger, Megan) (Entered: 08/07/2023)
2023-08-07
1
SO ORDERED, regarding D.I. 232 MOTION for Pro Hac Vice Appearance of Attorney Jeffrey S. Messing. Signed by Judge Matthew F Kennelly on 8/7/2023. (apk) (Entered: 08/07/2023)
2023-08-07
1
SO ORDERED
2023-08-07
1
No Actions
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
1
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
REDACTED VERSION of 229 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Appendix A, # 2 Ex. 1, # 3 Ex. 2, # 4 Ex. 3, # 5 Ex. 4, # 6 Ex. 5, # 7 Ex. 6, # 8 Ex. 7, # 9 Ex. 8, # 10 Ex. 9, # 11 Ex. 10, # 12 Ex. 11, # 13 Ex. 12, # 14 Ex. 13)(Dellinger, Megan) (Entered: 08/09/2023)
2023-08-09
2
[SEALED] ANSWERING BRIEF in Opposition re 228 MOTION to Enforce the Court's June 15 Order filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 8/17/2023. (Attachments: # 1 Appendix 1, # 2 Exhibit A, # 3 Exhibit B, # 4 Exhibit C)(DiBenedetto, Emily) (Entered: 08/10/2023)
2023-08-10
1
[SEALED] ANSWERING BRIEF in Opposition re 223 MOTION for Protective Order filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 8/21/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10)(Dellinger, Megan) (Entered: 08/14/2023)
2023-08-14
1
ORAL ORDER, The Court currently has telephonic hearings set for 8/17/2023 on plaintiff's motion to enforce the June 15 order (D.I. 228 ) and for 8/18/2023 on defendant's motion for protective order (D.I. 223 ). Both hearing dates are vacated. The case is set for a single telephonic hearing on both motions on 8/23/2023 at 8:30 AM Central Time. The following call-in number will be used: 888-684-8852; access code 746-1053. Ordered by Judge Matthew F Kennelly on 8/16/2023.(twk) (Entered: 08/16/2023)
2023-08-16
1
Oral Order AND ~Util - Set Deadlines/Hearings
2023-08-16
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Amended Rule 26(a) Initial Disclosures - filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 08/17/2023)
2023-08-17
1
REDACTED VERSION of 235 Answering Brief in Opposition, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 08/17/2023)
2023-08-17
1
MOTION for Judgment on the Pleadings on Defendants' Fifth Affirmative Defense Pursuant to Fed. R. Civ. P. 12(c) and 12(h) and to Strike the Related Expert Report of Teresa Stanek Rea - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 08/17/2023)
2023-08-17
1
[SEALED] OPENING BRIEF in Support re 240 MOTION for Judgment on the Pleadings on Defendants' Fifth Affirmative Defense Pursuant to Fed. R. Civ. P. 12(c) and 12(h) and to Strike the Related Expert Report of Teresa Stanek Rea filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 8/31/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)(Dellinger, Megan) (Entered: 08/17/2023)
2023-08-17
1
REDACTED VERSION of 236 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 08/21/2023)
2023-08-21
1
Motion Hearing AND Order on Motion for Miscellaneous Relief AND Order on Motion for Protective Order AND ~Util - Terminate Motions
2023-08-23
1
No Actions
Minute Entry: Telephonic motion hearing held on 8/23/2023. Oral ruling made on the plaintiff's motion to enforce court order 228 and the defendant's motion for protective order 223 . Defendant's motion for protective order 223 regarding certain proposed depositions is granted for the reason stated on the record. Plaintiff's motion to enforce June 15 court order 228 is denied for the reasons stated on the record. The Court clarifies that enforcing certain discovery requests relating to the "Patents in Suit" and "Asserted Patents" it intended to require production of information concerning the US patent applications that directly led to the issuance of the two patents in suit. (apk)
2023-08-23
1
No Actions
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
1
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
REDACTED VERSION of 241 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7)(Dellinger, Megan) (Entered: 08/24/2023)
2023-08-24
2
[SEALED] ANSWERING BRIEF in Opposition re 240 MOTION for Judgment on the Pleadings on Defendants' Fifth Affirmative Defense Pursuant to Fed. R. Civ. P. 12(c) and 12(h) and to Strike the Related Expert Report of Teresa Stanek Rea filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 9/7/2023. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(DiBenedetto, Emily) (Entered: 08/31/2023)
2023-08-31
1
[SEALED] REPLY BRIEF re 240 MOTION for Judgment on the Pleadings on Defendants' Fifth Affirmative Defense Pursuant to Fed. R. Civ. P. 12(c) and 12(h) and to Strike the Related Expert Report of Teresa Stanek Rea - filed by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 8, # 2 Ex. 9, # 3 Ex. 10)(Smith, Rodger) (Entered: 09/06/2023)
2023-09-06
1
REDACTED VERSION of 244 Answering Brief in Opposition,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 09/07/2023)
2023-09-07
1
NOTICE OF SERVICE of (1) Rebuttal Expert Report of Glen J. Weiss, M.D., M.B.A; (2) Rebuttal Expert Report of Frederick Hausheer M.D.; (3) Rebuttal Expert Report of Dr. William L. Jorgensen on Enablement and Written Description; (4) Expert Report of Robert L. Stoll; and (5) Responsive Expert Report of Daniel E. Troy - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 09/11/2023)
2023-09-11
1
NOTICE OF SERVICE of 1) Rebuttal Expert Report of Trever G. Bivona, M.D., Ph.D. regarding Non-Infringement of U.S. Patent Nos. 10,603,314 and 10,596,162 2) Rebuttal Expert Report of Pasi A. Janne, M.D., Ph.D. 3) Rebuttal Expert Report of Dr. Paul J. Reider regarding Secondary Considerations, Non-Infringement, and Damages 4) Rebuttal Expert Report of Carla S. Mulhern filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 09/11/2023)
2023-09-11
1
Joint STATUS REPORT by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 09/11/2023)
2023-09-11
1
REDACTED VERSION of 245 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 8, # 2 Ex. 9, # 3 Ex. 10)(Smith, Rodger) (Entered: 09/13/2023)
2023-09-13
1
REDACTED VERSION of 245 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 8, # 2 Ex. 9, # 3 Ex. 10)(Smith, Rodger) (Entered: 09/13/2023)
2023-09-13
2
REDACTED VERSION of 245 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 8, # 2 Ex. 9, # 3 Ex. 10)(Smith, Rodger) (Entered: 09/13/2023)
2023-09-13
2
REDACTED VERSION of 245 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 8, # 2 Ex. 9, # 3 Ex. 10)(Smith, Rodger) (Entered: 09/13/2023)
2023-09-13
2
NOTICE OF SERVICE of Defendants' Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 8 - 9) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 09/25/2023)
2023-09-25
1
MOTION for Pro Hac Vice Appearance of Attorney Alexis Adian Smith - filed by Puma Biotechnology, Inc.. (Dellinger, Megan) (Entered: 09/28/2023)
2023-09-28
1
SO ORDERED, re 252 MOTION for Pro Hac Vice Appearance of Attorney Alexis Adian Smith. Ordered by Judge Matthew F Kennelly on 9/28/2023. (twk) (Entered: 09/28/2023)
2023-09-28
1
SO ORDERED
2023-09-28
1
No Actions
NOTICE OF SERVICE of 1) Reply Expert Report of Dr. Paul J. Reider Regarding Invalidity of U.S. Patent Nos. 10,596,162 and 10,603,314 2) Reply Expert Report of Benjamin Levy, M.D. Regarding Invalidity of U.S. Patent Nos. 10,603,314 and 10,596,162 3) Reply Expert Report of David R. Taft, Ph.D. 4) Reply Expert Report of Pasi A. Janne, M.D., Ph.D. 5) Reply Expert Report of Scott M. Lassman 6) Reply Expert Report of Teresa Stanek Rea Regarding U.S. Patent Nos. 10,603,314 and 10,596,162 7) Reply Expert Report of Trever Bivona, M.D., Ph.D. Regarding U.S. Patent Nos. 10,603,314 and 10,596,162 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Keller, Karen) (Entered: 10/09/2023)
2023-10-09
1
NOTICE OF SERVICE of (1) Reply Expert Report of Alice Berger, Ph.D.; (2) Reply Expert Report of Frederick Hausheer M.D.; (3) Reply Expert Report of Mohan Rao, Ph.D.; and (4) Reply Expert Report of Glen J. Weiss, M.D., M.B.A. - filed by Puma Biotechnology, Inc., Wyeth LLC.(Smith, Rodger) (Entered: 10/09/2023)
2023-10-09
1
ORDER, the Court DENIES Puma's motion for judgment on the pleadings on AstraZeneca's fifth affirmative defense and also denies Puma's motion to strike the expert report of Teresa Stanek Rea (docket no. 240 ). Signed by Judge Matthew F Kennelly on 10/10/2023. (mpb) (Entered: 10/10/2023)
2023-10-10
1
Add Attorneys - PHV only
2023-10-11
1
No Actions
Pro Hac Vice Attorney Alexis Adian Smith for Puma Biotechnology, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
2023-10-11
1
No Actions
NOTICE to Take Deposition of Benjamin Levy on November 2, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Carla S. Mulhern on November 16, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of David R. Taft on November 1, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Pasi A. Janne on November 14, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Paul J. Reider on November 7, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Scott M. Lassman on October 17, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Trever Bivona on November 17, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Teresa Stanek Rea on November 8, 2023 filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Mr. Daniel E. Troy, Dr. Glen J. Weiss, Dr. Alice Berger, Ph.D., Dr. Mohan Rao, Mr. Robert L. Stoll, Dr. Frederick Hausheer and Dr. William L. Jorgensen on various dates filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 10/16/2023)
2023-10-16
1
STIPULATION and [Proposed] Order Regarding Case Dispositive Motions and Daubert Motions by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 11/28/2023)
2023-11-28
1
ORAL ORDER: The parties have submitted a stipulation and proposed order that appears to provide for summary judgment and Daubert briefing totaling 400 pages (200 pages per side). This is vastly more than is appropriate for this case and there has been no attempt to justify the proposed page limits. The Court will not approve the stipulation. The parties may file summary judgment and Daubert briefs totaling no more than 110 pages per side in the aggregate. The Court suggests that this be divided up 45/45/20 on each sides combined summary judgment and Daubert briefing but will allow the parties to revise that configuration by agreement. Signed by Judge Matthew F Kennelly on 11/28/2023. (mpb) (Entered: 11/29/2023)
2023-11-28
1
Oral Order AND ~Util - Terminate Motions
2023-11-29
1
No Actions
MOTION to Dismiss Based upon Lack of Article III Standing - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION to Dismiss Based upon Lack of Article III Standing - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
2
[SEALED] OPENING BRIEF in Support re 268 MOTION to Dismiss Based upon Lack of Article III Standing filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 12/26/2023. (Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION for Summary Judgment of Invalidity - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION for Summary Judgment of Invalidity - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
2
[SEALED] OPENING BRIEF in Support re 270 MOTION for Summary Judgment of Invalidity filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 12/26/2023. (Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] STATEMENT re 270 MOTION for Summary Judgment of Invalidity [Statement of Undisputed Facts In Support of Defendants' Motion for Summary Judgment of Invalidity] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
2
[SEALED] OPENING BRIEF in Support re 273 MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 12/26/2023. (Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] STATEMENT re 273 MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages [Statement of Undisputed Facts in Support of Defendants' Motion for Summary Judgment of Non-Infringement and No Pre-Issuance Damages] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION to Preclude [Defendants' Motion to Exclude Opinions of Mohan Rao, Ph.D.] - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION to Preclude [Defendants' Motion to Exclude Opinions of Mohan Rao, Ph.D.] - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
2
MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF CARLA S. MULHERN AND TREVER BIVONA, MOTION to Preclude - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] OPENING BRIEF in Support re 276 MOTION to Preclude [Defendants' Motion to Exclude Opinions of Mohan Rao, Ph.D.] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 12/26/2023. (Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] OPENING BRIEF in Support re 277 MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF CARLA S. MULHERN AND TREVER BIVONA MOTION to Preclude filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 12/26/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
MOTION to Preclude --PLAINTIFFS' MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF PASI A. JANNE AND CARLA S. MULHERN-- - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 270 MOTION for Summary Judgment of Invalidity, 273 MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages, 268 MOTION to Dismiss Based upon Lack of Article III Standing, 276 MOTION to Preclude [Defendants' Motion to Exclude Opinions of Mohan Rao, Ph.D.] [Declaration of Ashley Winkler in Support of Defendant's Motion to Dismiss, Motions for Summary Judgment, and Motion to Exclude Opinions of Mohan Rao, Ph.D.] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] OPENING BRIEF in Support re 280 MOTION to Preclude --PLAINTIFFS' MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF PASI A. JANNE AND CARLA S. MULHERN-- filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 12/26/2023. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 269 Opening Brief in Support, [Declaration of Carla S. Mulhern Regarding Expert Report] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 274 Opening Brief in Support, 271 Opening Brief in Support [Declaration of Dr. Pasi A. Janne Regarding Expert Reports] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 274 Opening Brief in Support, 271 Opening Brief in Support [Declaration of Dr. Paul J. Reider Regarding Expert Reports] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 271 Opening Brief in Support [Declaration of Dr. David R. Taft regarding Expert Reports] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 274 Opening Brief in Support, [Declaration of Dr. Trever Bivona Regarding Expert Reports] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 12/08/2023)
2023-12-08
1
MOTION for Summary Judgment - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] OPENING BRIEF in Support re 288 MOTION for Summary Judgment filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 12/26/2023. (Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] STATEMENT re 288 MOTION for Summary Judgment, 289 Opening Brief in Support by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
[SEALED] DECLARATION re 288 MOTION for Summary Judgment by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/08/2023)
2023-12-08
1
NOTICE of Withdrawal of Counsel by Puma Biotechnology, Inc., Wyeth LLC (Dellinger, Megan) (Entered: 12/13/2023)
2023-12-13
1
REDACTED VERSION of 283 Declaration by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 283 Declaration by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 284 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 284 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 284 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 284 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 285 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 285 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 285 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 285 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted, # 2 Exhibit B- redacted, # 3 Exhibit C- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 287 Declaration by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 287 Declaration by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 269 Opening Brief in Support, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 271 Opening Brief in Support by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 272 Statement, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 274 Opening Brief in Support, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 275 Statement, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 278 Opening Brief in Support, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 279 Opening Brief in Support,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 282 Opening Brief in Support, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 289 Opening Brief in Support by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 290 Statement by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 291 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Dellinger, Megan) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 286 Declaration by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 286 Declaration by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A- redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
1
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
REDACTED VERSION of 281 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1-redacted, # 2 Exhibit 2-redacted, # 3 Exhibit 3-redacted, # 4 Exhibit 4-redacted, # 5 Exhibit 5-redacted, # 6 Exhibit 6-redacted, # 7 Exhibit 7-redacted, # 8 Exhibit 8-redacted, # 9 Exhibit 9-redacted, # 10 Exhibit 10-redacted, # 11 Exhibit 11-redacted, # 12 Exhibit 12-redacted, # 13 Exhibit 13-redacted, # 14 Exhibit 14-redacted, # 15 Exhibit 15-redacted, # 16 Exhibit 16-redacted, # 17 Exhibit 17-redacted, # 18 Exhibit 18-redacted, # 19 Exhibit 19-redacted, # 20 Exhibit 20-redacted, # 21 Exhibit 21-redacted, # 22 Exhibit 22-redacted, # 23 Exhibit 23-redacted, # 24 Exhibit 24-redacted, # 25 Exhibit 25-redacted, # 26 Exhibit 26-redacted, # 27 Exhibit 27--redacted, # 28 Exhibit 28-redacted, # 29 Exhibit 29--redacted, # 30 Exhibit 30-redacted, # 31 Exhibit 31-redacted, # 32 Exhibit 32-redacted, # 33 Exhibit 33-redacted, # 34 Exhibit 34-redacted, # 35 Exhibit 35-redacted, # 36 Exhibit 36-redacted, # 37 Exhibit 37-redacted, # 38 Exhibit 38-redacted, # 39 Exhibit 39-redacted, # 40 Exhibit 40-redacted, # 41 Exhibit 41-redacted, # 42 Exhibit 42-redacted, # 43 Exhibit 43-redacted, # 44 Exhibit 44-redacted, # 45 Exhibit 45-redacted, # 46 Exhibit 46-redacted, # 47 Exhibit 47-redacted)(Keller, Karen) (Entered: 12/15/2023)
2023-12-15
2
[SEALED] ANSWERING BRIEF in Opposition re 276 MOTION to Preclude [Defendants' Motion to Exclude Opinions of Mohan Rao, Ph.D.] filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 1/19/2024. (Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] ANSWERING BRIEF in Opposition re 270 MOTION for Summary Judgment of Invalidity filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 1/19/2024. (Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] ANSWERING BRIEF in Opposition re 273 MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 1/19/2024. (Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] ANSWERING BRIEF in Opposition re 268 MOTION to Dismiss Based upon Lack of Article III Standing filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 1/19/2024. (Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] STATEMENT re 272 Statement, (Plaintiffs' Response to Defendants' Statement of Undisputed Material Facts and Plaintiffs' Statement of Additional Disputed Material Facts That Preclude Summary Judgment on Invalidity) - by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] STATEMENT re 275 Statement, (Plaintiffs' Response to Defendants' Statement of Undisputed Material Facts and Plaintiffs' Statement of Additional Disputed Material Facts That Preclude Summary Judgment of Noninfringement and No Pre-Issuance Damages) by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] DECLARATION re 311 Answering Brief in Opposition, 310 Answering Brief in Opposition, 312 Answering Brief in Opposition, 313 Answering Brief in Opposition -- Declaration of Jason G. Winchester -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3, # 4 Ex. 4, # 5 Ex. 5, # 6 Ex. 6, # 7 Ex. 7, # 8 Ex. 8, # 9 Ex. 9, # 10 Ex. 10, # 11 Ex. 11, # 12 Ex. 12, # 13 Ex. 13, # 14 Ex. 14, # 15 Ex. 15, # 16 Ex. 16, # 17 Ex. 17, # 18 Ex. 18, # 19 Ex. 19, # 20 Ex. 20, # 21 Ex. 21, # 22 Ex. 22, # 23 Ex. 23, # 24 Ex. 24, # 25 Ex. 25, # 26 Ex. 26, # 27 Ex. 27, # 28 Ex. 28, # 29 Ex. 29, # 30 Ex. 30, # 31 Ex. 31, # 32 Ex. 32, # 33 Ex. 33, # 34 Ex. 34, # 35 Ex. 35, # 36 Ex. 36, # 37 Ex. 37, # 38 Ex. 38, # 39 Ex. 39, # 40 Ex. 40, # 41 Ex. 41, # 42 Ex. 42, # 43 Ex. 43, # 44 Ex. 44, # 45 Ex. 45, # 46 Ex. 46, # 47 Ex. 47, # 48 Ex. 48, # 49 Ex. 49)(Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] DECLARATION re 312 Answering Brief in Opposition, 311 Answering Brief in Opposition -- Declaration of Frederick H. Hausheer, M.D. Regarding Expert Reports -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C)(Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] DECLARATION re 312 Answering Brief in Opposition, 311 Answering Brief in Opposition -- Declaration of Glen J. Wiess, M.D. Regarding Expert Reports -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C)(Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] DECLARATION re 311 Answering Brief in Opposition -- Declaration of William L. Jorgensen Regarding Expert Report -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. A)(Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] DECLARATION re 312 Answering Brief in Opposition, -- Declaration of Alice Berger, Ph.D. Regarding Expert Report -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. A)(Dellinger, Megan) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] ANSWERING BRIEF in Opposition re 277 MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF CARLA S. MULHERN AND TREVER BIVONA MOTION to Preclude filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 1/19/2024. (DiBenedetto, Emily) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] ANSWERING BRIEF in Opposition re 280 MOTION to Preclude --PLAINTIFFS' MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF PASI A. JANNE AND CARLA S. MULHERN-- filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 1/19/2024. (DiBenedetto, Emily) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] ANSWERING BRIEF in Opposition re 288 MOTION for Summary Judgment filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 1/19/2024. (DiBenedetto, Emily) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] STATEMENT re 290 Statement [Defendants' Response to Plaintiffs' Concise Statement of Undisputed Material Facts in Support of Plaintiffs' Motion for Summary Judgment] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 01/12/2024)
2024-01-12
1
[SEALED] DECLARATION re 322 Answering Brief in Opposition, 323 Answering Brief in Opposition, 321 Answering Brief in Opposition, [Declaration of Ashley Winkler in Support of Defendants' Opposition to Plaintiffs' Motion for Summary Judgment Regarding Advice-Of-Counsel Defense and Motions to Exclude Certain Expert Testimony] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 48, # 2 Exhibit 49, # 3 Exhibit 50, # 4 Exhibit 51, # 5 Exhibit 52, # 6 Exhibit 53, # 7 Exhibit 54, # 8 Exhibit 55, # 9 Exhibit 56, # 10 Exhibit 57, # 11 Exhibit 58, # 12 Exhibit 59, # 13 Exhibit 60, # 14 Exhibit 61, # 15 Exhibit 62, # 16 Exhibit 63, # 17 Exhibit 64, # 18 Exhibit 65, # 19 Exhibit 66, # 20 Exhibit 67, # 21 Exhibit 68, # 22 Exhibit 69, # 23 Exhibit 70, # 24 Exhibit 71, # 25 Exhibit 72, # 26 Exhibit 73, # 27 Exhibit 74, # 28 Exhibit 75, # 29 Exhibit 76, # 30 Exhibit 77, # 31 Exhibit 78, # 32 Exhibit 79, # 33 Exhibit 80, # 34 Exhibit 81, # 35 Exhibit 82, # 36 Exhibit 83, # 37 Exhibit 84, # 38 Exhibit 85, # 39 Exhibit 86, # 40 Exhibit 87, # 41 Exhibit 88, # 42 Exhibit 89, # 43 Exhibit 90)(DiBenedetto, Emily) (Entered: 01/12/2024)
2024-01-12
1
STIPULATION TO EXTEND TIME to submit public versions of D.I. Nos. 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324 and 325 to January 26, 2024 - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 01/18/2024)
2024-01-18
1
SO ORDERED, re 326 STIPULATION TO EXTEND TIME to submit public versions of D.I. Nos. 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324 and 325 to January 26, 2024 filed by AstraZeneca Pharmaceuticals, LP, AstraZeneca AB. Ordered by Judge Matthew F Kennelly on 1/18/2024. (mpb) (Entered: 01/18/2024)
2024-01-18
1
SO ORDERED AND ~Util - Terminate Motions
2024-01-18
1
No Actions
REDACTED VERSION of 310 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 311 Answering Brief in Opposition by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 312 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 313 Answering Brief in Opposition by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 314 Statement, by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 315 Statement, by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 316 Declaration,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41, # 42 Exhibit 42, # 43 Exhibit 43, # 44 Exhibit 44, # 45 Exhibit 45, # 46 Exhibit 46, # 47 Exhibit 47, # 48 Exhibit 48, # 49 Exhibit 49)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 317 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 317 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 317 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 317 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 318 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 318 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 318 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 318 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 319 Declaration by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 319 Declaration by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 320 Declaration by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 320 Declaration by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 01/26/2024)
2024-01-26
2
REDACTED VERSION of 321 Answering Brief in Opposition, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 322 Answering Brief in Opposition, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 323 Answering Brief in Opposition by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 324 Statement, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 01/26/2024)
2024-01-26
1
REDACTED VERSION of 325 Declaration,,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 01/26/2024)
2024-01-26
1
[SEALED] REPLY BRIEF re 280 MOTION to Preclude --PLAINTIFFS' MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF PASI A. JANNE AND CARLA S. MULHERN-- filed by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 10 - AZ-PW-TAG00425938 ("Wu 2017"))(Dellinger, Megan) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] REPLY BRIEF re 277 MOTION TO EXCLUDE CERTAIN EXPERT TESTIMONY OF CARLA S. MULHERN AND TREVER BIVONA MOTION to Preclude filed by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 19 - 2023-09-08 - Bivona Rebuttal Expert Report, # 2 Ex. 20 - Rao deposition transcript (11-9-23), # 3 Ex. 21 - Bivona deposition transcript (11-17-23), # 4 Ex. 22 - 2022-02-28 Defs' Initial Rule 26(a) Disclosures)(Dellinger, Megan) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] REPLY BRIEF re 288 MOTION for Summary Judgment filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] DECLARATION re 345 Reply Brief, 346 Reply Brief, 344 Reply Brief, -- Declaration of Jason G. Winchester -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 15 - Email dated May 26, 2021 (AZ-PW-TAG00419699), # 2 Exhibit 16 - American Bar Ass'n Landslide Vol. 10, No. 2 (2017))(Dellinger, Megan) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] REPLY BRIEF re 268 MOTION to Dismiss Based upon Lack of Article III Standing filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] REPLY BRIEF re 270 MOTION for Summary Judgment of Invalidity filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] REPLY BRIEF re 273 MOTION for Summary Judgment of Non-Infringement and No Pre-Issuance Damages filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] REPLY BRIEF re 276 MOTION to Preclude [Defendants' Motion to Exclude Opinions of Mohan Rao, Ph.D.] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/02/2024)
2024-02-02
1
[SEALED] DECLARATION re 349 Reply Brief, 348 Reply Brief [Declaration of Ashley Winkler in Support of Defendants' Replies to Defendants' Motion to Dismiss and Motion for Summary Judgment of Invalidity] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit D-91, # 2 Exhibit D-92)(DiBenedetto, Emily) (Entered: 02/02/2024)
2024-02-02
1
REDACTED VERSION of 344 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 10 - AZ-PW-TAG00425938)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 344 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 10 - AZ-PW-TAG00425938)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 345 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 19 - Bivona Rebuttal Expert Report, # 2 Ex. 20 - Rao deposition transcript, # 3 Ex. 21 - Bivona deposition transcript, # 4 Ex. 22 - Defs' Initial Rule 26(a) Disclosures)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 345 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 19 - Bivona Rebuttal Expert Report, # 2 Ex. 20 - Rao deposition transcript, # 3 Ex. 21 - Bivona deposition transcript, # 4 Ex. 22 - Defs' Initial Rule 26(a) Disclosures)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 345 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 19 - Bivona Rebuttal Expert Report, # 2 Ex. 20 - Rao deposition transcript, # 3 Ex. 21 - Bivona deposition transcript, # 4 Ex. 22 - Defs' Initial Rule 26(a) Disclosures)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 345 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 19 - Bivona Rebuttal Expert Report, # 2 Ex. 20 - Rao deposition transcript, # 3 Ex. 21 - Bivona deposition transcript, # 4 Ex. 22 - Defs' Initial Rule 26(a) Disclosures)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 345 Reply Brief, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 19 - Bivona Rebuttal Expert Report, # 2 Ex. 20 - Rao deposition transcript, # 3 Ex. 21 - Bivona deposition transcript, # 4 Ex. 22 - Defs' Initial Rule 26(a) Disclosures)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 346 Reply Brief by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 347 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 15 - AZ-PW-TAG00419699, # 2 Ex. 16 - Attorney-Client Privilege for In-House Counsel)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 347 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 15 - AZ-PW-TAG00419699, # 2 Ex. 16 - Attorney-Client Privilege for In-House Counsel)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 347 Declaration, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Ex. 15 - AZ-PW-TAG00419699, # 2 Ex. 16 - Attorney-Client Privilege for In-House Counsel)(Dellinger, Megan) (Entered: 02/09/2024)
2024-02-09
2
REDACTED VERSION of 348 Reply Brief by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 349 Reply Brief by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 350 Reply Brief by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 351 Reply Brief by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/09/2024)
2024-02-09
1
REDACTED VERSION of 352 Declaration, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 02/09/2024)
2024-02-09
1
STIPULATION and [Proposed] Order Regarding Preparation of Final Pretrial Order by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 02/15/2024)
2024-02-15
1
STIPULATION AND ORDER regarding D.I. 362 STIPULATION and Proposed Order Regarding Preparation of Final Pretrial Order. Signed by Judge Matthew F Kennelly on 2/15/2024. (apk) (Entered: 02/15/2024)
2024-02-15
1
ORAL ORDER: Counsel are directed to cause a USB drive with the complete and unredacted version of their summary judgment and Daubert filings to Judge Kennelly's chambers in Chicago for overnight delivery (to arrive on 2/21/2024). Each filing should have all exhibits bookmarked in the PDF version included on the USB drive. The address is: Judge Matthew Kennelly; US District Court; 219 South Dearborn St.; Room 2188; Chicago IL 60604. Signed by Judge Matthew F Kennelly on 2/20/2024. (apk) (Entered: 02/20/2024)
2024-02-20
1
Oral Order
2024-02-20
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Bethany K. Biesenthal - filed by Puma Biotechnology, Inc.. (Dellinger, Megan) (Entered: 03/01/2024)
2024-03-01
1
Pro Hac Vice Fee - Credit Card Payment received for Bethany K. Biesenthal. ( re 365 MOTION for Pro Hac Vice Appearance of Attorney Bethany K. Biesenthal )( Payment of $ 50, receipt number ADEDC-4351752).(Dellinger, Megan) (Entered: 03/01/2024)
2024-03-01
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-03-01
1
No Actions
SO ORDERED
2024-03-01
1
No Actions
SO ORDERED, re 365 MOTION for Pro Hac Vice Appearance of Attorney Bethany K. Biesenthal filed by Puma Biotechnology, Inc. Signed by Judge Matthew F Kennelly on 03/01/2024. (smg)
2024-03-01
1
No Actions
Add Attorneys - PHV only
2024-03-04
1
No Actions
Pro Hac Vice Attorney Bethany K. Biesenthal for Puma Biotechnology, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
2024-03-04
1
No Actions
MOTION to Limit AstraZeneca's Prior Art Invalidity Defenses in Advance of Trial - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 03/12/2024)
2024-03-12
1
OPENING BRIEF in Support re 367 MOTION to Limit AstraZeneca's Prior Art Invalidity Defenses in Advance of Trial filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/26/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Dellinger, Megan) (Entered: 03/12/2024)
2024-03-12
1
OPENING BRIEF in Support re 367 MOTION to Limit AstraZeneca's Prior Art Invalidity Defenses in Advance of Trial filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/26/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Dellinger, Megan) (Entered: 03/12/2024)
2024-03-12
2
OPENING BRIEF in Support re 367 MOTION to Limit AstraZeneca's Prior Art Invalidity Defenses in Advance of Trial filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/26/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Dellinger, Megan) (Entered: 03/12/2024)
2024-03-12
2
OPENING BRIEF in Support re 367 MOTION to Limit AstraZeneca's Prior Art Invalidity Defenses in Advance of Trial filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/26/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Dellinger, Megan) (Entered: 03/12/2024)
2024-03-12
2
OPENING BRIEF in Support re 367 MOTION to Limit AstraZeneca's Prior Art Invalidity Defenses in Advance of Trial filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/26/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Dellinger, Megan) (Entered: 03/12/2024)
2024-03-12
2
MOTION to Compel AstraZeneca to Provide Supplemental Sales Data - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 03/13/2024)
2024-03-13
1
OPENING BRIEF in Support re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Dellinger, Megan) (Entered: 03/13/2024)
2024-03-13
1
OPENING BRIEF in Support re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Dellinger, Megan) (Entered: 03/13/2024)
2024-03-13
2
OPENING BRIEF in Support re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Dellinger, Megan) (Entered: 03/13/2024)
2024-03-13
2
ORAL ORDER: Defendant is directed to file a response to plaintiffs' motion to compel production of supplemental sales data 369 by 3/20/2024. No reply is to be filed unless the Court requests a reply. Plaintiffs have also filed a motion to limit defendant's prior art invalidity defenses 367 . The Court advises that it expects to rule on the pending summary judgment motions in no more than 7 or 8 days from now. Further briefing on the motion to limit is deferred pending that ruling. The Court advises however that any briefing on that motion will necessarily have to take place on an expedited basis given the approaching trial date. A telephonic status hearing is set for 3/22/2024 at 8:30 AM Central time. The following call-in number will be used: 888-684-8852; access code 746-1053. (A Status Conference is set for 3/22/2024 at 08:30 AM in Telephonically before Judge Matthew F Kennelly). Signed by Judge Matthew F Kennelly on 03/13/2024. (vfm) (Entered: 03/13/2024)
2024-03-13
1
Oral Order AND ~Util - Set Deadlines AND ~Util - Set Hearings
2024-03-13
1
No Actions
MEMORANDUM OPINION AND ORDER: The Court grants AstraZeneca's motion to dismiss (dkt. 268 ) with respect to Puma Biotechnology but denies the motion to dismiss with respect to Wyeth. The Court denies AstraZeneca's motion for summary judgment on invalidity (dkt. 270 ). The Court denies AstraZeneca's motion for summary judgment on non-infringement (dkt. 273 ), except with respect to the issue of pre-issuance damages, on which the Court rules in favor of AstraZeneca. The Court denies Wyeth's motion for summary judgment on AstraZeneca's advice-of-counsel defense (dkt. 288 ). Finally, the Court denies Wyeth's motions to exclude the testimony of Mulhern, Dr. Bivona, and Dr. Jnne, (dkt. 277 & dkt. 280 ) and denies AstraZeneca's motion to exclude the testimony of Dr. Rao (dkt. 276 ). The case is set for a telephonic status hearing on March 22, 2024 at 8:30 a.m. The following call-in number will be used: 888-684-8852, access code 746-1053. Trial counsel should participate in the hearing. Prior to that date, the parties are to confer regarding the motion to limit prior art defenses to attempt to agree upon appropriate limitations. Signed by Judge Matthew F Kennelly on 3/18/2024. (mpb) (Entered: 03/18/2024)
2024-03-18
1
ANSWERING BRIEF in Opposition re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Main Document 373 replaced on 3/21/2024 per counsel) (mrr). (Entered: 03/20/2024)
2024-03-20
1
ANSWERING BRIEF in Opposition re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Main Document 373 replaced on 3/21/2024 per counsel) (mrr). (Entered: 03/20/2024)
2024-03-20
2
ANSWERING BRIEF in Opposition re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Main Document 373 replaced on 3/21/2024 per counsel) (mrr). (Entered: 03/20/2024)
2024-03-20
2
ANSWERING BRIEF in Opposition re 369 MOTION to Compel AstraZeneca to Provide Supplemental Sales Data filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 3/27/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Main Document 373 replaced on 3/21/2024 per counsel) (mrr). (Entered: 03/20/2024)
2024-03-20
2
Oral Order: Telephonic status and motion hearing held on 3/22/2024. Plaintiff's motion to compel 369 is granted to the following extent: defendants are directed to promptly produce the requested sales and related data through 12/31/2023. Counsel are to work out a schedule for updates to damages expert reports based on defendants' production of updated information. The Court also discussed trial logistics with the parties. The trial will be a 5-day jury trial as previously ordered. Trial time is limited to 11 hours per side. Time spent on jury selection and the jury instruction conference does not count against this allocation. Time will be counted whenever a party is arguing before the jury or the Court (including on evidentiary objections); questioning a witness; and presenting deposition testimony. On depositions the parties will need to provide the Court with a percentage breakdown for any deposition testimony that is presented to the jury. Opening statements are limited to 30 minutes per side. Closing arguments are limited to 1 hour per side total. Any request to modify these limitations must be made promptly. Counsel are to be present and ready to go each trial day at 8:45 AM. The trial day will run until approximately 5:00 PM. If necessary the jury instruction conference will be held after the jury leaves at the end of a trial day. For the preliminary and final instructions the Court will need the parties to be prepared to project them for the jury when the Court reads them (before opening statements and before closing arguments). The final pretrial conference remains set for 4/30/2024 at 9:30 AM Central Time. The Court will send out a video invitation a few days before the conference. Ordered by Judge Matthew F. Kennelly on 03/22/2024. (smg) (Entered: 03/22/2024)
2024-03-22
1
Order on Motion to Compel AND Status Conference AND ~Util - Terminate Motions
2024-03-22
1
No Actions
MOTION to Dismiss Based upon lack of subject matter jurisdiction following the Court's order dismissing Puma for lack of Article III standing (D.I. 372) - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Russell, Andrew) (Entered: 03/27/2024)
2024-03-27
1
MOTION to Dismiss Based upon lack of subject matter jurisdiction following the Court's order dismissing Puma for lack of Article III standing (D.I. 372) - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Russell, Andrew) (Entered: 03/27/2024)
2024-03-27
2
OPENING BRIEF in Support re 375 MOTION to Dismiss Based upon lack of subject matter jurisdiction following the Court's order dismissing Puma for lack of Article III standing (D.I. 372) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 4/10/2024. (Attachments: # 1 Exhibit A)(Russell, Andrew) (Entered: 03/27/2024)
2024-03-27
1
OPENING BRIEF in Support re 375 MOTION to Dismiss Based upon lack of subject matter jurisdiction following the Court's order dismissing Puma for lack of Article III standing (D.I. 372) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 4/10/2024. (Attachments: # 1 Exhibit A)(Russell, Andrew) (Entered: 03/27/2024)
2024-03-27
2
NOTICE of Appearance of Anthony M. Insogna, Jason G. Winchester, Gasper J. LaRosa, Bethany K. Biesenthal, John C. Evans, Alexis Adian Smith, Michelle B. Smit, Jeffrey S. Messing, Daniele San Romn, Meredith A. Stewart, and Miguel A. Alvarez by Wyeth LLC (Smith, Rodger) (Entered: 04/02/2024)
2024-04-02
1
MOTION for Pro Hac Vice Appearance of Attorney John M. Michalik and Jennifer L. Swize - filed by Puma Biotechnology, Inc., Wyeth LLC. (Smith, Rodger) (Entered: 04/02/2024)
2024-04-02
1
Pro Hac Vice Fee - Credit Card Payment received for John M. Michalik and Jennifer L. Swize. ( re 378 MOTION for Pro Hac Vice Appearance of Attorney John M. Michalik and Jennifer L. Swize )( Payment of $ 100, receipt number ADEDC-4374741).(Smith, Rodger) (Entered: 04/02/2024)
2024-04-02
1
SO ORDERED D.I. 378 MOTION for Pro Hac Vice Appearance of Attorney John M. Michalik and Jennifer L. Swize filed by Wyeth LLC, Puma Biotechnology, Inc. Ordered by Judge Matthew F Kennelly on 04/02/2024. (smg) (Entered: 04/02/2024)
2024-04-02
1
SO ORDERED
2024-04-02
1
No Actions
-District Court Pro Hac Vice Fee - 02 Attorneys Credit Card Payment
2024-04-02
1
No Actions
Add Attorneys - PHV only
2024-04-02
1
No Actions
Pro Hac Vice Attorneys Jennifer L. Swize and John M. Michalik for Puma Biotechnology, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
2024-04-02
1
No Actions
[SEALED] Proposed Pretrial Order (Joint) by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Attachment 1A, # 2 Attachment 1B, # 3 Attachment 2, # 4 Attachment 3, # 5 Attachment 4, # 6 Attachment 5, # 7 Attachment 6, # 8 Attachment 7, # 9 Attachments 8A-8B, # 10 Attachment 9, # 11 Attachment 10, # 12 Attachment 11, # 13 Attachment 12A, # 14 Attachment 12B)(Dellinger, Megan) (Entered: 04/09/2024)
2024-04-09
1
[SEALED] ANSWERING BRIEF in Opposition re 375 MOTION to Dismiss Based upon lack of subject matter jurisdiction following the Court's order dismissing Puma for lack of Article III standing (D.I. 372) filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 4/17/2024. (Dellinger, Megan) (Entered: 04/10/2024)
2024-04-10
1
STATEMENT -- Joint Request Regarding Juror Questionnaire -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 04/10/2024)
2024-04-10
1
STATEMENT -- Joint Request Regarding Juror Questionnaire -- by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 04/10/2024)
2024-04-10
2
ORAL ORDER: The Court sets this case for a telephonic status hearing on 4/15/2024 at 8:30 AM Central time to discuss certain matters relating to jury selection in the upcoming trial. The following call-in number will be used: 888-684-8852; access code 746-1053. Ordered by Judge Matthew F Kennelly on 04/11/2024. (smg) (Entered: 04/11/2024)
2024-04-11
1
Oral Order AND ~Util - Set Hearings
2024-04-11
1
No Actions
NOTICE OF SERVICE of Defendants' Notice Pursuant to 35 U.S.C. § 282 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(Russell, Andrew) (Entered: 04/12/2024)
2024-04-12
1
REPLY BRIEF re 375 MOTION to Dismiss Based upon lack of subject matter jurisdiction following the Court's order dismissing Puma for lack of Article III standing (D.I. 372) filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 04/14/2024)
2024-04-14
1
Status Conference
2024-04-15
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Telephonic status hearing regarding jury selection held on 4/15/2024. The parties later advised Judge Kennelly's courtroom deputy clerk that they are withdrawing their request for a pre-voir dire written questionnaire. (smg)
2024-04-15
1
No Actions
NOTICE OF SERVICE of Updated Calculations and Related Tabs to the Expert Report of Mohan Rao, Ph.D. filed by Puma Biotechnology, Inc., Wyeth LLC.(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
1
[SEALED] MOTION in Limine - filed by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
1
[SEALED] MOTION in Limine [Defendants' Omnibus Motion in Limine] - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 04/16/2024)
2024-04-16
1
[SEALED] DECLARATION re 389 MOTION in Limine [Defendants' Omnibus Motion in Limine] [Declaration of Ashley Winkler In Support of Defendants' Omnibus Motion in Limine] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Exhibit 33, # 34 Exhibit 34, # 35 Exhibit 35, # 36 Exhibit 36, # 37 Exhibit 37, # 38 Exhibit 38, # 39 Exhibit 39, # 40 Exhibit 40, # 41 Exhibit 41)(Keller, Karen) (Entered: 04/16/2024)
2024-04-16
1
[SEALED] OPENING BRIEF in Support re 388 MOTION in Limine filed by Puma Biotechnology, Inc., Wyeth LLC.Answering Brief/Response due date per Local Rules is 4/30/2024. (Attachments: # 1 Ex. 1 - 2023-07-28 - Excerpted Janne Opening Expert Report (CONF), # 2 Ex. 2 - Taft Excerpted deposition transcript (11-1-23), # 3 Ex. 3 - 2023-09-08 - Excerpted Hausheer Rebuttal Expert Report (CONF), # 4 Ex. 4 - 2023-10-06 - Excerpted Reider Reply Expert Report CONF, # 5 Ex. 5 - 2023-09-08 - Excerpted Bivona Rebuttal Expert Report (CONF), # 6 Ex. 6 - 2023-07-28 - Excerpted Weiss Opening Expert Report (CONF), # 7 Ex. 7 - 2023-10-06 - Excerpted Weiss Reply Expert Report (CONF), # 8 Ex. 8 - 2023-07-28 - Excerpted Taft Opening Expert Report (CONF), # 9 Ex. 9 - Ghiorghiu Excerpted deposition transcript (4-25-23), # 10 Ex. 10 - 2023-09-08 - Excerpted Janne Rebuttal Expert Report (CONF), # 11 Ex. 11 - 2023-09-08 - Excerpted Reider Rebuttal Expert Report (CONF), # 12 Ex. 12 - 2023-07-28 - Excerpted Reider Opening Expert Report (CONF), # 13 Ex. 13 - 2024-04-10 - Smit email to counsel, # 14 14 - JTX-001, # 15 15- JTX-002, # 16 16 - PX-021, # 17 17 - PX-448, # 18 18 - DTX-0075, # 19 19 - DTX-0080, # 20 20 - DTX-0087, # 21 21 - DTX-0095, # 22 22 - DTX-0096, # 23 23 - DTX-0097, # 24 24 - DTX-0100, # 25 25 - DTX-0103, # 26 26 - DTX-0105, # 27 27 - DTX-0106, # 28 28 - DTX-0107, # 29 29 - DTX-0115, # 30 30 - DTX-0118, # 31 31 - DTX-0121, # 32 32 - DTX-0128, # 33 33 - DTX-0129, # 34 34 - DTX-0130, # 35 35 - DTX-0138, # 36 36 - DTX-0140, # 37 37 - DTX-0143, # 38 38 - DTX-0144, # 39 39 - DTX-0145, # 40 40 - DTX-0156, # 41 41 - DTX-0160, # 42 42 - DTX-0168, # 43 43 - DTX-0185, # 44 44 - DTX-0196, # 45 45 - DTX-0210, # 46 46 - DTX-0320, # 47 47- DTX-0350, # 48 48 - DTX-0351, # 49 49 - DTX-0519, # 50 50 - DTX-0690, # 51 51 - DTX-0761, # 52 52 - DTX-0762, # 53 53- DTX-0763, # 54 54 - DTX-0764, # 55 55 - DTX-0765, # 56 56 - DTX-0876, # 57 57 - DTX-1243, # 58 58 - DTX-1280)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
1
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
1
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
REDACTED VERSION of 381 Proposed Pretrial Order, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 REDACTED Attachment 1A, # 2 REDACTED Attachment 1B, # 3 REDACTED Attachment 2, # 4 REDACTED Attachment 3, # 5 REDACTED Attachment 4, # 6 REDACTED Attachment 5, # 7 REDACTED Attachment 6, # 8 REDACTED Attachment 7, # 9 REDACTED Attachment 8A-8B, # 10 REDACTED Attachment 9, # 11 REDACTED Attachment 10, # 12 REDACTED Attachment 11, # 13 REDACTED Attachment 12A, # 14 REDACTED Attachment 12B)(Dellinger, Megan) (Entered: 04/16/2024)
2024-04-16
2
ORAL ORDER: The parties are reminded that each side's response to the opposing side's motions in limine is to be filed by 4/23/2024. The parties are also directed to deliver to Judge Kennelly's Chicago chambers (Room 2188 of the Dirksen Courthouse) on 4/24/2023 a single USB drive that contains the complete and unredacted versions of each side's motions in limine and supporting materials; each side's response to the opposing side's motion; and the final pretrial order. Each exhibit is to be bookmarked in the PDF version of the respective submission. Signed by Judge Matthew F Kennelly on 4/17/2024. (rlr) (Entered: 04/17/2024)
2024-04-17
1
REDACTED VERSION of 382 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 04/17/2024)
2024-04-17
1
Oral Order
2024-04-17
1
No Actions
NOTICE OF SERVICE of Updated Appendices A - B and Updated Exhibits 1, 8, 9, 10, 14, 15, 17, 19, 30, 31, 32, 33, 34, 35, 36, and 38 to the Rebuttal Expert Report of Carla S. Mulhern filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.(DiBenedetto, Emily) (Entered: 04/22/2024)
2024-04-22
1
REDACTED VERSION of 388 MOTION in Limine by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
1
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
1
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 391 Opening Brief in Support,,,,,,,, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 JTX-001, # 15 JTX-002, # 16 PX-021, # 17 PX-0448, # 18 DTX-0075, # 19 DTX-0080, # 20 DTX-0087, # 21 DTX-0095, # 22 DTX-0096, # 23 DTX-0097, # 24 DTX-0100, # 25 DTX-0103, # 26 DTX-0105, # 27 DTX-0106, # 28 DTX-0107, # 29 DTX-0115, # 30 DTX-0118, # 31 DTX-0121, # 32 DTX-0128, # 33 DTX-0129, # 34 DTX-0130, # 35 DTX-0138, # 36 DTX-0140, # 37 DTX-0143, # 38 DTX-0144, # 39 DTX-0145, # 40 DTX-0156, # 41 DTX-0160, # 42 DTX-0168, # 43 DTX-0185, # 44 DTX-0196, # 45 DTX-0210, # 46 DTX-0320, # 47 DTX-0350, # 48 DTX-0351, # 49 DTX-0519, # 50 DTX-0690, # 51 DTX-0761, # 52 DTX-0762, # 53 DTX-0763, # 54 DTX-0764, # 55 DTX-0765, # 56 DTX-0876, # 57 DTX-1243, # 58 DTX-1280)(Dellinger, Megan) (Entered: 04/23/2024)
2024-04-23
2
REDACTED VERSION of 389 MOTION in Limine [Defendants' Omnibus Motion in Limine] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 04/23/2024)
2024-04-23
1
REDACTED VERSION of 390 Declaration,,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 04/23/2024)
2024-04-23
1
[SEALED] ANSWERING BRIEF in Opposition re 389 MOTION in Limine [Defendants' Omnibus Motion in Limine] - filed by Puma Biotechnology, Inc., Wyeth LLC.Reply Brief due date per Local Rules is 4/30/2024. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Ex. 14, # 5 Ex. 15, # 6 Ex. 16, # 7 Ex. 17, # 8 Ex. 18, # 9 Ex. 19, # 10 Ex. 20, # 11 Ex. 21, # 12 Ex. 22, # 13 Ex. 23, # 14 Ex. 24)(Smith, Rodger) (Entered: 04/23/2024)
2024-04-23
1
[SEALED] ANSWERING BRIEF in Opposition re 388 MOTION in Limine filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 4/30/2024. (Russell, Andrew) (Entered: 04/23/2024)
2024-04-23
1
[SEALED] DECLARATION re 401 Answering Brief in Opposition [Declaration of Alexander Trzeciak in Support of Defendants' Opposition to Plaintiff and Counterclaim Defendants' Motions in Limine] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1 - DTX-0035, # 2 Exhibit 2 - Wilner Tr., # 3 Exhibit 3 - DTX-0143, # 4 Exhibit 4 - Genuine Enabling Tech. LLC, D.I. 303, # 5 Exhibit 5 - Reider Reply, # 6 Exhibit 6 - Weiss Op., # 7 Exhibit 7 - Weiss Tr., # 8 Exhibit 8 - Mulhern Rebuttal, # 9 Exhibit 9 - Reider Rebuttal, # 10 Exhibit 10 - Skiers Choice brief, # 11 Exhibit 11 - 2023.08.23 Hrg. Tr., # 12 Exhibit 12 - Alban Tr., # 13 Exhibit 13 - Bivona Rebuttal, # 14 Exhibit 14 - Jnne Op., # 15 Exhibit 15 - Reider Op., # 16 Exhibit 16 - Taft Op.)(DiBenedetto, Emily) (Entered: 04/23/2024)
2024-04-23
1
MEMORANDUM AND ORDER: The Court grants the defendants' motion to dismiss their declaratory judgment counterclaims against Puma Biotechnology, Inc. for lack of jurisdiction ([dkt. no. 375 ). See Order for further details. Signed by Judge Matthew F Kennelly on 04/29/2024. (vfm) (Entered: 04/29/2024)
2024-04-29
1
ORAL ORDER: Video pretrial conference scheduled for 4/30/2024 at 9:30 a.m. Central. Members of the public and media will be able to call in to listen to the conference. The call-in number is (650) 479-3207 and the call-in ID is 23183877358##. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court-issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Signed by Judge Matthew F Kennelly on 04/29/2024. (vfm) (Entered: 04/29/2024)
2024-04-29
1
MOTION for Pro Hac Vice Appearance of Attorney Robert T. McMullen - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 04/29/2024)
2024-04-29
1
Pro Hac Vice Fee - Credit Card Payment received for Robert T. McMullen. ( re 405 MOTION for Pro Hac Vice Appearance of Attorney Robert T. McMullen )( Payment of $ 50, receipt number ADEDC-4395244).(Keller, Karen) (Entered: 04/29/2024)
2024-04-29
1
SO ORDERED, regarding D.I. 405 MOTION for Pro Hac Vice Appearance of Attorney Robert T. McMullen. Signed by Judge Matthew F Kennelly on 04/29/2024. (vfm) (Entered: 04/29/2024)
2024-04-29
1
ORDER: The Court grants defendants' motions in limine (D.I. 389 ) 1, 3, and 11 and denies defendants' motions in limine 2, 5, 6, 8, and 9. Defendants' motions 4, 7, and 10 and all of plaintiff's motions remain for determination.at the final pretrial conference. See Order for further details. Signed by Judge Matthew F Kennelly on 04/29/2024. (vfm) (Entered: 04/29/2024)
2024-04-29
1
Oral Order AND ~Util - Set Hearings
2024-04-29
1
No Actions
SO ORDERED
2024-04-29
1
No Actions
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-04-29
1
No Actions
MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Russell, Andrew) (Entered: 04/30/2024)
2024-04-30
1
MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Text of Proposed Order)(Russell, Andrew) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
1
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 400 Answering Brief in Opposition, by Puma Biotechnology, Inc., Wyeth LLC. (Attachments: # 1 PX-263, # 2 DTX-0513, # 3 DTX-0747, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24)(Dellinger, Megan) (Entered: 04/30/2024)
2024-04-30
2
REDACTED VERSION of 401 Answering Brief in Opposition by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 04/30/2024)
2024-04-30
1
REDACTED VERSION of 402 Declaration,,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 04/30/2024)
2024-04-30
1
Add Attorneys - PHV only
2024-04-30
1
No Actions
Pro Hac Vice Attorney Robert T. McMullen for AstraZeneca AB, Robert T. McMullen for AstraZeneca Pharmaceuticals, LP added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (vfm)
2024-04-30
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Pretrial Conference held on 4/30/2024. Oral argument heard and rulings made on the record regarding remaining motions in limine with the exception of certain motions on which the Court will issue a written ruling. A video motion hearing is set for 5/3/2024 at 9:15 a.m. Central time. Dr. Alban is directed to appear for the hearing. The Court will send out a video conference invitation a few days before the hearing. (mpb)
2024-04-30
1
No Actions
[SEALED] NOTICE of Supplemental Citation in Support of Wyeth's Motion in Limine No. 4 by Wyeth LLC re 391 Opening Brief in Support,,,,,,,, 388 MOTION in Limine (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 05/01/2024)
2024-05-01
1
STATEMENT re 413 Notice (Other) [Defendants' Response to Wyeth's Notice of Supplemental Citation Regarding Wyeth's Motion in Limine No. 4] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1)(Russell, Andrew) (Entered: 05/02/2024)
2024-05-02
1
STATEMENT re 413 Notice (Other) [Defendants' Response to Wyeth's Notice of Supplemental Citation Regarding Wyeth's Motion in Limine No. 4] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit 1)(Russell, Andrew) (Entered: 05/02/2024)
2024-05-02
2
Joint STATEMENT Regarding Disputed Preliminary Jury Instructions by Puma Biotechnology, Inc., Wyeth LLC. (Dellinger, Megan) (Entered: 05/03/2024)
2024-05-03
1
Minute Entry for proceedings held before Judge Matthew F Kennelly - Video hearing regarding trial witness held on 5/3/2024. Defense motion in limine no. 4 is denied for the reasons stated on the record. The parties are directed to jointly file a report with their disputed preliminary jury instructions issues by close of business on 5/3/2024. The parties are directed to meet and confer to narrow the exhibits to a reasonable number. (mpb)
2024-05-03
1
No Actions
MOTION for Exemption of Persons from the Court's May 15, 2023 Standing Order on Personal Devices - filed by Wyeth LLC. (Dellinger, Megan) (Entered: 05/07/2024)
2024-05-07
1
SO ORDERED, re D.I. 409 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Ordered by Judge Matthew F Kennelly on 5/7/2024. (mpb) (Entered: 05/07/2024)
2024-05-07
1
SO ORDERED, re D.I. 416 MOTION for Exemption of Persons from the Court's May 15, 2023 Standing Order on Personal Devices. Ordered by Judge Matthew F Kennelly on 5/7/2024. (mpb) (Entered: 05/07/2024)
2024-05-07
1
ORDER Ruling on Motions in Limine (D.I. 388 and D.I. 389 ). The parties are expected and directed to instruct their witnesses regarding the Court's in limine rulings impacting their testimony to avoid running afoul of the rulings during the upcoming trial. (See Order for further details) Signed by Judge Matthew F Kennelly on 5/7/2024. (mpb) (Entered: 05/07/2024)
2024-05-07
1
ORAL ORDER: The Court has reviewed the Joint Statement Regarding Disputed Preliminary Jury Instructions (D.E. 415 ) and rules as follows. (1) The Court adopts defendants' proposal on Instruction 10.2 bullet point 1. (2) The Court adopts plaintiff's proposal on Instruction 10.2 bullet point 2. (3) The Court adopts plaintiff's proposal on Instruction 10.5 bullet. The Court does not see a need to include in the preliminary instructions a prompt regarding the dispute over the priority date. (4) The parties are directed to prepare a final version of the preliminary instructions consistent with these rulings; send a Word and a PDF version of the final version to Judge Kennelly's proposed order e-mail address; and determine which party will project these (along with the FJC patent system video) to the jury when they are read before opening statements. Signed by Judge Matthew F Kennelly on 05/07/2024. (vfm) (Entered: 05/07/2024)
2024-05-07
1
SO ORDERED
2024-05-07
1
No Actions
Oral Order
2024-05-07
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Eric R. Sonnenschein - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/08/2024)
2024-05-08
1
Pro Hac Vice Fee - Credit Card Payment received for Eric R. Sonnenschein. ( re 421 MOTION for Pro Hac Vice Appearance of Attorney Eric R. Sonnenschein )( Payment of $ 50, receipt number ADEDC-4402442).(Keller, Karen) (Entered: 05/08/2024)
2024-05-08
1
SO ORDERED, re 421 MOTION for Pro Hac Vice Appearance of Attorney Eric R. Sonnenschein filed by AstraZeneca Pharmaceuticals, LP, AstraZeneca AB. Ordered by Judge Matthew F Kennelly on 5/8/2024. (mpb) (Entered: 05/08/2024)
2024-05-08
1
REDACTED VERSION of 413 Notice (Other) by Wyeth LLC. (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 05/08/2024)
2024-05-08
1
REDACTED VERSION of 413 Notice (Other) by Wyeth LLC. (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 05/08/2024)
2024-05-08
2
SO ORDERED AND ~Util - Terminate Motions
2024-05-08
1
No Actions
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-05-08
1
No Actions
Add Attorneys - PHV only
2024-05-08
1
No Actions
Pro Hac Vice Attorney Eric R. Sonnenschein for AstraZeneca AB and AstraZeneca Pharmaceuticals, LP added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-05-08
1
No Actions
EXHIBIT re 381 Proposed Pretrial Order, --Attachment 9 - [Proposed] Voir Dire-- by Wyeth LLC. (Dellinger, Megan) (Entered: 05/10/2024)
2024-05-10
1
Joint STIPULATION Regarding Uncontested Facts for Presentation to the Jury by Wyeth LLC. (Dellinger, Megan) (Entered: 05/10/2024)
2024-05-10
1
MOTION for Exemption of Persons from the Court's May 15, 2023 Standing Order on Personal Devices - filed by Wyeth LLC. (Dellinger, Megan) (Entered: 05/10/2024)
2024-05-10
1
SO ORDERED, re 427 MOTION for Exemption of Persons from the Court's May 15, 2023 Standing Order on Personal Devices filed by Wyeth LLC. Ordered by Judge Matthew F Kennelly on 5/10/2024. (mpb) (Entered: 05/10/2024)
2024-05-10
1
[SEALED] MOTION for Reconsideration re 419 Order,, Terminate Motions, [Defendants' Motion for Reconsideration and/or Clarification of Orders Granting Plaintiff's Motions in Limine Nos. 1 & 3] - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 05/10/2024)
2024-05-10
1
[SEALED] DECLARATION re 429 MOTION for Reconsideration re 419 Order,, Terminate Motions, [Defendants' Motion for Reconsideration and/or Clarification of Orders Granting Plaintiff's Motions in Limine Nos. 1 & 3] [Declaration of Robert T. McMullen in Support of Defendants' Motion for Reconsideration and/or Clarification of Orders Granting Plaintiffs' Motions in Limine Nos. 1 & 3] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Russell, Andrew) (Entered: 05/10/2024)
2024-05-10
1
ORAL ORDER, Defendants waived until 4:30 PM Eastern time on the last business day before trial (May 10) to seek reconsideration of not one but two rulings the Court made 3 full days ago (2:30 PM Eastern time on May 7). The Court gives notice that the time spent considering this motion is likely to be counted as part of defendants trial time. Plaintiff is directed to file a response to the motion by 5:00 PM Eastern time on Saturday May 11. Defendants may not file a reply unless the Court specifically asks for one in advance. The parties should not expect a ruling before the first day of trial (May 13). The Court reserves the right to rule that the motion is untimely and/or relies on points that have been forfeited or waived. Signed by Judge Matthew F Kennelly on 5/10/2024. (nmg) (Entered: 05/10/2024)
2024-05-10
1
SO ORDERED AND ~Util - Terminate Motions
2024-05-10
1
No Actions
Oral Order AND ~Util - Set Briefing Schedule - open,ans,reply,surreply
2024-05-10
1
No Actions
[SEALED] ANSWERING BRIEF in Opposition re 429 MOTION for Reconsideration re 419 Order,, Terminate Motions, [Defendants' Motion for Reconsideration and/or Clarification of Orders Granting Plaintiff's Motions in Limine Nos. 1 & 3] filed by Wyeth LLC.Reply Brief due date per Local Rules is 5/20/2024. (Dellinger, Megan) (Entered: 05/11/2024)
2024-05-11
1
EXHIBIT re 381 Proposed Pretrial Order, --[Revised] Attachment 6 - Wyeth's Trial Exhibit List-- by Wyeth LLC. (Dellinger, Megan) (Entered: 05/12/2024)
2024-05-12
1
EXHIBIT re 381 Proposed Pretrial Order, --[Revised] Attachment 5- Joint Trial Exhibit List -- by Wyeth LLC. (Dellinger, Megan) (Entered: 05/12/2024)
2024-05-12
1
[SEALED] OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP [AstraZeneca's Objections to Wyeth's Deposition Designations for Monday May 13, 2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Keller, Karen) (Entered: 05/13/2024)
2024-05-13
1
ORDER: the Court overrules defendants' motion for reconsideration and/or clarification (dkt. no. 429 ), with the exception that the defendants' experts may rely on the Carmi 2010 reference to, as they contended, "describe the state of the art at the priority date and to show that the specification fails to disclose representative species and to enable the full scope of the claims." Defs.' Opp. to Mots. In Limine at 5. Signed by Judge Matthew F Kennelly on 5/13/2024. (mpb) (Entered: 05/13/2024)
2024-05-13
1
[SEALED] Joint STATEMENT --Joint Submission Regarding Deposition Designations for Tuesday, May 14, 2024-- by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 05/13/2024)
2024-05-13
1
~Util - Set Scheduling Order Deadlines
2024-05-13
1
No Actions
Jury Trial - Begun
2024-05-13
1
No Actions
Remark: Jury trial days of May 14, 2024 - May 17, 2024, have been added. (mpb)
2024-05-13
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Jury Trial Day 1 held on 5/13/2024. (Court Reporter Carolyn Cox.) (mpb)
2024-05-13
1
No Actions
[SEALED] OBJECTIONS by Wyeth LLC -- Wyeth's Objections to Exhibits for Tuesday May 14, 2024 --. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 05/14/2024)
2024-05-14
1
Preliminary Jury Instructions read to the Jury on May 13, 2024. (mpb) (Entered: 05/14/2024)
2024-05-14
1
Jury Trial - Held
2024-05-14
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Jury Trial Day 2 held on 5/14/2024. (Court Reporter Carolyn Cox.) (mpb)
2024-05-14
1
No Actions
[SEALED] OBJECTIONS by Wyeth LLC -- Objections to Exhibits for Wednesday May 15, 2024 --. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K)(Dellinger, Megan) (Entered: 05/15/2024)
2024-05-15
1
[SEALED] OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP to 440 Objections, [AstraZeneca's Responses to Wyeth's Objections to Exhibits for Wednesday May 15, 2024]. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Russell, Andrew) (Entered: 05/15/2024)
2024-05-15
1
[SEALED] OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP Objections to Demonstrative Exhibits for Thursday May 16, 2024. (Attachments: # 1 Exhibit A PDX-WLJ-4, # 2 Exhibit B Jorgensen Rebuttal Report, # 3 Exhibit C Reider Reply Report)(Russell, Andrew) (Entered: 05/15/2024)
2024-05-15
1
Minute Entry for proceedings held before Judge Matthew F Kennelly - Jury Trial Day 3 held on 5/15/2024. (Court Reporter Carolyn Cox.) (mpb)
2024-05-15
1
No Actions
RESPONSE TO OBJECTIONS by Wyeth LLC re 442 Objections, Wyeth's Response to AstraZeneca's Objections to Wyeth's Expert Demonstrative for Thursday May 16, 2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Dellinger, Megan) (Entered: 05/16/2024)
2024-05-16
1
RESPONSE TO OBJECTIONS by Wyeth LLC re 442 Objections, Wyeth's Response to AstraZeneca's Objections to Wyeth's Expert Demonstrative for Thursday May 16, 2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Dellinger, Megan) (Entered: 05/16/2024)
2024-05-16
2
RESPONSE TO OBJECTIONS by Wyeth LLC re 442 Objections, Wyeth's Response to AstraZeneca's Objections to Wyeth's Expert Demonstrative for Thursday May 16, 2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Dellinger, Megan) (Entered: 05/16/2024)
2024-05-16
2
STATEMENT of the Deposition Transcripts Played at Trial May 13 and 14, 2024 by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Attachment 5 replaced on 5/17/2024) (mpb). (Entered: 05/16/2024)
2024-05-16
1
STATEMENT of the Deposition Transcripts Played at Trial May 13 and 14, 2024 by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Attachment 5 replaced on 5/17/2024) (mpb). (Entered: 05/16/2024)
2024-05-16
2
STATEMENT of the Deposition Transcripts Played at Trial May 13 and 14, 2024 by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Attachment 5 replaced on 5/17/2024) (mpb). (Entered: 05/16/2024)
2024-05-16
2
STATEMENT of the Deposition Transcripts Played at Trial May 13 and 14, 2024 by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Attachment 5 replaced on 5/17/2024) (mpb). (Entered: 05/16/2024)
2024-05-16
2
STATEMENT of the Deposition Transcripts Played at Trial May 13 and 14, 2024 by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Attachment 5 replaced on 5/17/2024) (mpb). (Entered: 05/16/2024)
2024-05-16
2
STATEMENT of the Deposition Transcripts Played at Trial May 13 and 14, 2024 by Wyeth LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Attachment 5 replaced on 5/17/2024) (mpb). (Entered: 05/16/2024)
2024-05-16
2
ORAL ORDER: On or before June 4, 2024, the respective parties are hereby instructed to submit a joint status report. A 3-day Bench Trial has been scheduled to begin June 17, 2024, at 9:30 a.m. CST in Chicago, Illinois. Ordered by Judge Matthew F Kennelly on 05/16/2024. (vfm) (Entered: 05/16/2024)
2024-05-16
1
STIPULATION TO EXTEND TIME to submit public versions of D.I. 429, 430, 432, 435, 437, 438, 440, 441 and 442 to May 31, 2024 - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 05/16/2024)
2024-05-16
1
Exhibit List --Joint List of Admitted Trial Exhibits-- by Wyeth LLC. (Smith, Rodger) (Entered: 05/16/2024)
2024-05-16
1
Jury Trial - Held
2024-05-16
1
No Actions
Oral Order AND ~Util - Set Scheduling Order Deadlines
2024-05-16
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Jury Trial Day 4 held on 5/16/2024. (Court Reporter Carolyn Cox.) (mpb)
2024-05-16
1
No Actions
[SEALED] MOTION for Judgment as a Matter of Law Pursuant to Federal Rule of Civil Procedure 50(a) - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
1
Exhibit List -- Plaintiff's Trial Exhibit List-- by Wyeth LLC. (Smith, Rodger) (Entered: 05/17/2024)
2024-05-17
1
Exhibit List --Joint Trial Exhibit List-- by Wyeth LLC. (Smith, Rodger) (Entered: 05/17/2024)
2024-05-17
1
STATEMENT of the Deposition Transcripts Played at Trial May 14, 2024 by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
1
STATEMENT of the Deposition Transcripts Played at Trial May 14, 2024 by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
2
STATEMENT of the Deposition Transcripts Played at Trial May 14, 2024 by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
2
STATEMENT of the Deposition Transcripts Played at Trial May 14, 2024 by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
2
STATEMENT of the Deposition Transcripts Played at Trial May 14, 2024 by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
2
STATEMENT of the Deposition Transcripts Played at Trial May 14, 2024 by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
2
Exhibit List -- Defendants Trial Exhibit List by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 05/17/2024)
2024-05-17
1
FINAL Jury Instructions read to the Jury on 5/16/2024. (mpb) (Entered: 05/17/2024)
2024-05-17
1
FINAL VERDICT SHEET (Blank). (mpb) (Entered: 05/17/2024)
2024-05-17
1
ORAL ORDER: The Court is not entering a final judgment on the verdict at this time because certain equitable defenses remain for trial to the Court. The Court reserves the right to enter a non-final judgment addressing the claims and defenses that have been determined and asks the parties for their thoughts and input on the advisability of this and the language for such a non-final judgment if the Court determines to enter one. A joint status report in this regard is to be filed by 5/22/2024. Motions for new trial and/or for judgment as a matter of law based on the jury's determinations and verdict are to be filed by 6/14/2024.Ordered by Judge Matthew F Kennelly on 5/17/20224. (mpb) (Entered: 05/17/2024)
2024-05-17
1
[SEALED] JURY VERDICT. (mpb) (Entered: 05/17/2024)
2024-05-17
1
[REDACTED] JURY VERDICT. (mpb) (Entered: 05/17/2024)
2024-05-17
1
[SEALED] Jury Note. (mpb) (Entered: 05/17/2024)
2024-05-17
1
- CORRECTING ENTRY
2024-05-17
1
No Actions
Jury Trial - Completed
2024-05-17
1
No Actions
Oral Order AND ~Util - Set Deadlines
2024-05-17
1
No Actions
CORRECTING ENTRY: Per Counsel's request, Attachment 5 to D.I. 444 has been replaced to reflect the correct Exhibit E. (mpb)
2024-05-17
1
No Actions
Minute Entry for proceedings held before Judge Matthew F Kennelly - Jury Trial completed on 5/17/2024. (Court Reporter Carolyn Cox.) (mpb)
2024-05-17
1
No Actions
Joint STATUS REPORT by Wyeth LLC. (Dellinger, Megan) (Entered: 05/22/2024)
2024-05-22
1
ORAL ORDER: The Court has reviewed the parties status report. A telephonic case management conference to discuss the matters in the report is set for 5/28/2024 at 8:30 AM Central time (9:30 AM Eastern time). The following call-in number will be used for the hearing: 888-684-8852; access code 746-1053. Signed by Judge Matthew F Kennelly on 5/23/2024. (rlr) (Entered: 05/23/2024)
2024-05-23
1
Oral Order AND ~Util - Set Deadlines/Hearings
2024-05-23
1
No Actions
STIPULATION TO EXTEND TIME to submit a public version of D.I. 448 to May 31, 2024 - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/24/2024)
2024-05-24
1
SO ORDERED, re 461 STIPULATION TO EXTEND TIME to submit a public version of D.I. 448 to May 31, 2024 filed by AstraZeneca Pharmaceuticals, LP, AstraZeneca AB.Ordered by Judge Matthew F Kennelly on 5/24/2024. (mpb) (Entered: 05/24/2024)
2024-05-24
1
SO ORDERED AND ~Util - Terminate Motions
2024-05-24
1
No Actions
NON-FINAL JUDGMENT in favor of Wyeth LLC against AstraZeneca AB, AstraZeneca Pharmaceuticals, LP in the amount of $107,500,000. (See Judgment for further details) Signed by Judge Matthew F Kennelly on 5/28/2024. (mpb) (Entered: 05/28/2024)
2024-05-28
1
Telephone Conference AND ~Util - Set Deadlines
2024-05-28
1
No Actions
Minute Entry: Telephonic case management conference held. (1) The Court directs entry of a Non-Final Judgment as discussed during the conference. (2) Defendants' JMOL/new trial motion is to be combined in a single filing. The opening memorandum is due 6/14/2024 and may be up to 30 pages long; the response memorandum is due 6/28/2024 and may be up to 30 pages long; and the reply memorandum is due 7/5/2024 and may be up to 15 pages long. (3) Plaintiff's anticipated motion(s) seeking supplemental damages; ongoing royalties; and/or interest are to be combined in a single filing. The opening memorandum is due 6/25/2024 and may be up to 20 pages long; the response memorandum is due 7/9/2024 and may be up to 20 pages long; and the reply memorandum is due 7/16/2024 and may be up to 10 pages long. (4) The Court declines to defer filing of a bill of costs until after an appeal and directs the parties to confer and agree upon an appropriate schedule and provide it to Judge Kennellys Chicago courtroom deputy clerk. (5) The parties are given until 6/10/2024 to submit revised proposed findings of fact and conclusions of law for the upcoming bench trial. The Court will not be asking for post-hearing briefs. (6) The Court will determine whether to set another telephonic status hearing after it gets the upcoming status report regarding the bench trial. (Court Reporter N/A.) (mpb)
2024-05-28
1
No Actions
NOTICE of Lodging of Defendants' Jury Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 - DDX2, # 2 Exhibit 2 - DDX3, # 3 Exhibit 3 - DDX4, # 4 Exhibit 4 - DDX5, # 5 Exhibit 5 - DDX6)(Russell, Andrew) (Entered: 05/31/2024)
2024-05-31
1
NOTICE of Lodging of Defendants' Jury Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 - DDX2, # 2 Exhibit 2 - DDX3, # 3 Exhibit 3 - DDX4, # 4 Exhibit 4 - DDX5, # 5 Exhibit 5 - DDX6)(Russell, Andrew) (Entered: 05/31/2024)
2024-05-31
2
NOTICE of Lodging of Defendants' Jury Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 - DDX2, # 2 Exhibit 2 - DDX3, # 3 Exhibit 3 - DDX4, # 4 Exhibit 4 - DDX5, # 5 Exhibit 5 - DDX6)(Russell, Andrew) (Entered: 05/31/2024)
2024-05-31
2
NOTICE of Lodging of Defendants' Jury Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 - DDX2, # 2 Exhibit 2 - DDX3, # 3 Exhibit 3 - DDX4, # 4 Exhibit 4 - DDX5, # 5 Exhibit 5 - DDX6)(Russell, Andrew) (Entered: 05/31/2024)
2024-05-31
2
NOTICE of Lodging of Defendants' Jury Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 - DDX2, # 2 Exhibit 2 - DDX3, # 3 Exhibit 3 - DDX4, # 4 Exhibit 4 - DDX5, # 5 Exhibit 5 - DDX6)(Russell, Andrew) (Entered: 05/31/2024)
2024-05-31
2
NOTICE of Lodging of Defendants' Jury Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 - DDX2, # 2 Exhibit 2 - DDX3, # 3 Exhibit 3 - DDX4, # 4 Exhibit 4 - DDX5, # 5 Exhibit 5 - DDX6)(Russell, Andrew) (Entered: 05/31/2024)
2024-05-31
2
REDACTED VERSION of 432 Answering Brief in Opposition, by Wyeth LLC. (Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 437 Statement by Wyeth LLC. (Attachments: # 1 Exs. A-E)(Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 437 Statement by Wyeth LLC. (Attachments: # 1 Exs. A-E)(Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
2
REDACTED VERSION of 438 Objections by Wyeth LLC. (Attachments: # 1 Exs. A-E)(Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 438 Objections by Wyeth LLC. (Attachments: # 1 Exs. A-E)(Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
2
REDACTED VERSION of 440 Objections, by Wyeth LLC. (Attachments: # 1 Exs. A-K)(Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 440 Objections, by Wyeth LLC. (Attachments: # 1 Exs. A-K)(Dellinger, Megan) (Entered: 05/31/2024)
2024-05-31
2
REDACTED VERSION of 429 MOTION for Reconsideration re 419 Order,, Terminate Motions, [Defendants' Motion for Reconsideration and/or Clarification of Orders Granting Plaintiff's Motions in Limine Nos. 1 & 3] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 430 Declaration,, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 435 Objections, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 441 Objections, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 448 MOTION for Judgment as a Matter of Law Pursuant to Federal Rule of Civil Procedure 50(a) by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/31/2024)
2024-05-31
1
REDACTED VERSION of 442 Objections, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 05/31/2024)
2024-05-31
1
Joint STATUS REPORT by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/04/2024)
2024-06-04
1
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
1
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
2
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
2
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
2
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
2
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
2
NOTICE of Lodging of Wyeth's Jury Trial Demonstratives by Wyeth LLC (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Dellinger, Megan) (Entered: 06/05/2024)
2024-06-05
2
STATEMENT [(A) Joint Errata and (B) AstraZeneca's Disputed Supplemental Errata] by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/05/2024)
2024-06-05
1
STIPULATION Regarding the Bill of Costs by Wyeth LLC. (Dellinger, Megan) (Entered: 06/07/2024)
2024-06-07
1
ORAL ORDER: The case is set for a telephonic status hearing on 6/11/2024 at 8:20 AM Central time (9:20 AM Eastern time) to discuss scheduling issues relating to the bench trial based on the parties' recent status report. Ordered by Judge Matthew F Kennelly on 6/10/2024. (mpb) (Entered: 06/10/2024)
2024-06-10
1
ORAL ORDER: Parties are too call-in to the following number for the telephonic status hearing on 6/11/2024 at 8:20 AM Central time (9:20 AM Eastern Time): 650-479-3207; access code 980-394-33 Signed by Judge Matthew F Kennelly on 6/10/2024. (apk) (Entered: 06/10/2024)
2024-06-10
1
[SEALED] Proposed Findings of Fact by Wyeth LLC. (Dellinger, Megan) (Entered: 06/10/2024)
2024-06-10
1
[SEALED] Proposed Findings of Fact by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 06/10/2024)
2024-06-10
1
Oral Order AND ~Util - Set Hearings
2024-06-10
1
No Actions
Oral Order
2024-06-10
1
No Actions
1 - Terminate Scheduling Order Deadlines AND Status Conference AND ~Util - Set Scheduling Order Deadlines
2024-06-11
1
No Actions
Oral Order: Telephonic status hearing held on 6/11/2024. The bench trial starting date of 6/18/2024 is vacated and reset to 6/20/2024 at 9:15 a.m. in Judge Kennelly's Chicago courtroom (2103) as agreed by the parties. If the bench trial is not completed on 6/20/2024 then it will be completed on 6/25/2024. The parties have already filed proposed findings of fact and conclusion of law. Any designated deposition is to be submitted 6/14/2024. In addition (though not discussed during today's hearing) the parties are directed to provide the Court and opposing counsel advance notice of any testimony during the jury trial upon which they intend to rely in connection with the bench trial. (mpb)
2024-06-11
1
No Actions
MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
1
OPENING BRIEF in Support re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Answering Brief/Response due date per Local Rules is 6/28/2024. (Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
1
[SEALED] Joint OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP to Status Conference,,, Terminate Scheduling Order Deadlines,,, Set Scheduling Order Deadlines,, [Joint Submission of Objections Regarding Deposition Designations for Bench Trial]. (Attachments: # 1 Exhibit A- Kwak, # 2 Exhibit B-Settleman, # 3 Exhibit C-Wilner, # 4 Exhibit D-Wong, # 5 Exhibit E-Cross, # 6 Exhibit F-Finlay, # 7 Exhibit G-Ward, # 8 Exhibit H-Sordella, # 9 Exhibit I-Haber)(DiBenedetto, Emily) (Entered: 06/14/2024)
2024-06-14
1
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
1
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
Joint NOTICE of Trial Testimony Upon Which the Parties Intend to Rely by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit 1 May 13, 2024 Jury Trial Transcript, # 2 Exhibit 2 May 14, 2024 Jury Trial Transcript, # 3 Exhibit 3 May 15, 2024 Jury Trial Transcript, # 4 Exhibit 4 May 16, 2024 Jury Trial Transcript, # 5 Exhibit 5 May 17, 2024 Jury Trial Transcript, # 6 Exhibit 6 Dr. Sordella Deposition Designation, # 7 Exhibit 7 Dr. Cross Deposition Designation, # 8 Exhibit 8 Dr. Ghiorghiu Deposition Designation, # 9 Exhibit 9 Dr. Haber Deposition Designation, # 10 Exhibit 10 Dr. Ward Deposition Designation)(Russell, Andrew) (Entered: 06/14/2024)
2024-06-14
2
REDACTED VERSION of 482 Proposed Findings of Fact by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/17/2024)
2024-06-17
1
REDACTED VERSION of 481 Proposed Findings of Fact by Wyeth LLC. (Dellinger, Megan) (Entered: 06/17/2024)
2024-06-17
1
[SEALED] OBJECTIONS by Wyeth LLC --Wyeth's Objections to Demonstratives and Expected Testimony for Thursday, June 20, 2024--. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Dellinger, Megan) (Entered: 06/19/2024)
2024-06-19
1
OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP AstraZeneca's Objections to Wyeth's Exhibits for June 20, 2024 Bench Trial. (Attachments: # 1 Exhibit A DTX-036)(Russell, Andrew) (Entered: 06/19/2024)
2024-06-19
1
OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP AstraZeneca's Objections to Wyeth's Exhibits for June 20, 2024 Bench Trial. (Attachments: # 1 Exhibit A DTX-036)(Russell, Andrew) (Entered: 06/19/2024)
2024-06-19
2
[SEALED] RESPONSE TO OBJECTIONS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP re 489 Objections, [AstraZeneca's Response to Wyeth's Objections to Demonstratives and Expected Testimony for Thursday, June 20, 2024]. (Attachments: # 1 Exhibit 1)(DiBenedetto, Emily) Modified on 6/20/2024 (mpb). (Entered: 06/20/2024)
2024-06-20
1
- CORRECTING ENTRY
2024-06-20
1
No Actions
CORRECTING ENTRY: Per counsel's request, D.I. 491 has been placed under seal to reflect correct filing procedure. (mpb)
2024-06-20
1
No Actions
STIPULATION TO EXTEND TIME to submit public versions of D.I. 485, 489 and 491 to July 3, 2024 - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 06/21/2024)
2024-06-21
1
SO ORDERED, regarding 492 STIPULATION TO EXTEND TIME to submit public versions of D.I. 485, 489 and 491 to July 3, 2024. Signed by Judge Matthew F Kennelly on 6/21/2024. (apk) (Entered: 06/21/2024)
2024-06-21
1
Bench Trial - Held
2024-06-21
1
No Actions
SO ORDERED
2024-06-21
1
No Actions
Minute Entry for a Bench Trial held before Judge Matthew F Kennelly - Bench Trial held on 6/20/2024 and continued to 6/25/2024 at 10:30 a.m. (apk)
2024-06-21
1
No Actions
[SEALED] MOTION Under Rule 59(e) for Supplemental Damages, Interest, and Ongoing Royalties - filed by Wyeth LLC. (Attachments: # 1 Proposed Order)(Smith, Rodger) (Entered: 06/25/2024)
2024-06-25
1
[SEALED] OPENING BRIEF in Support re 494 MOTION Under Rule 59(e) for Supplemental Damages, Interest, and Ongoing Royalties - filed by Wyeth LLC.Answering Brief/Response due date per Local Rules is 7/9/2024. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G, # 8 Ex. H, # 9 Ex. I, # 10 Ex. J, # 11 Ex. K, # 12 Ex. L, # 13 Ex. M, # 14 Ex. N, # 15 Ex. O)(Smith, Rodger) (Entered: 06/25/2024)
2024-06-25
1
Bench Trial - Completed
2024-06-25
1
No Actions
Oral Order: Bench trial regarding certain affirmative defenses continued and completed on 6/25/2024. The case is taken under advisement. Ordered by Judge Matthew F. Kennelly. (mpb)
2024-06-25
1
No Actions
NOTICE of Lodging of AstraZeneca's Bench Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiBenedetto, Emily) (Entered: 06/26/2024)
2024-06-26
1
NOTICE of Lodging of AstraZeneca's Bench Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiBenedetto, Emily) (Entered: 06/26/2024)
2024-06-26
2
NOTICE of Lodging of AstraZeneca's Bench Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiBenedetto, Emily) (Entered: 06/26/2024)
2024-06-26
2
NOTICE of Lodging of AstraZeneca's Bench Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiBenedetto, Emily) (Entered: 06/26/2024)
2024-06-26
2
NOTICE of Lodging of AstraZeneca's Bench Trial Demonstratives by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiBenedetto, Emily) (Entered: 06/26/2024)
2024-06-26
2
NOTICE of Demonstrative Lodging (Bench Trial) by Wyeth LLC (Attachments: # 1 Ex. A- Weiss Direct Demonstratives, # 2 Ex. B- Troy Direct Demonstratives)(Dellinger, Megan) (Entered: 06/26/2024)
2024-06-26
1
NOTICE of Demonstrative Lodging (Bench Trial) by Wyeth LLC (Attachments: # 1 Ex. A- Weiss Direct Demonstratives, # 2 Ex. B- Troy Direct Demonstratives)(Dellinger, Megan) (Entered: 06/26/2024)
2024-06-26
2
NOTICE of Demonstrative Lodging (Bench Trial) by Wyeth LLC (Attachments: # 1 Ex. A- Weiss Direct Demonstratives, # 2 Ex. B- Troy Direct Demonstratives)(Dellinger, Megan) (Entered: 06/26/2024)
2024-06-26
2
ANSWERING BRIEF in Opposition re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by Wyeth LLC.Reply Brief due date per Local Rules is 7/5/2024. (Attachments: # 1 Ex. A - 04-27-23 Cross - Wyeth initial and AZ counter designations, # 2 Ex. C - 04-25-23 Ghiorghiu - Wyeth initial and AZ counter designations, # 3 Ex. D - 04-12-23 Miller- Wyeth initial and AZ counter designations, # 4 Ex. E - 05-05-23 Ward - Wyeth initial and AZ counter designations, # 5 Ex. A - 04-26-23 Haber - AZ's Statement of Deposition Transcripts Played at Trial May 14, 2024)(Dellinger, Megan) (Entered: 06/28/2024)
2024-06-28
1
ANSWERING BRIEF in Opposition re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by Wyeth LLC.Reply Brief due date per Local Rules is 7/5/2024. (Attachments: # 1 Ex. A - 04-27-23 Cross - Wyeth initial and AZ counter designations, # 2 Ex. C - 04-25-23 Ghiorghiu - Wyeth initial and AZ counter designations, # 3 Ex. D - 04-12-23 Miller- Wyeth initial and AZ counter designations, # 4 Ex. E - 05-05-23 Ward - Wyeth initial and AZ counter designations, # 5 Ex. A - 04-26-23 Haber - AZ's Statement of Deposition Transcripts Played at Trial May 14, 2024)(Dellinger, Megan) (Entered: 06/28/2024)
2024-06-28
2
ANSWERING BRIEF in Opposition re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by Wyeth LLC.Reply Brief due date per Local Rules is 7/5/2024. (Attachments: # 1 Ex. A - 04-27-23 Cross - Wyeth initial and AZ counter designations, # 2 Ex. C - 04-25-23 Ghiorghiu - Wyeth initial and AZ counter designations, # 3 Ex. D - 04-12-23 Miller- Wyeth initial and AZ counter designations, # 4 Ex. E - 05-05-23 Ward - Wyeth initial and AZ counter designations, # 5 Ex. A - 04-26-23 Haber - AZ's Statement of Deposition Transcripts Played at Trial May 14, 2024)(Dellinger, Megan) (Entered: 06/28/2024)
2024-06-28
2
ANSWERING BRIEF in Opposition re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by Wyeth LLC.Reply Brief due date per Local Rules is 7/5/2024. (Attachments: # 1 Ex. A - 04-27-23 Cross - Wyeth initial and AZ counter designations, # 2 Ex. C - 04-25-23 Ghiorghiu - Wyeth initial and AZ counter designations, # 3 Ex. D - 04-12-23 Miller- Wyeth initial and AZ counter designations, # 4 Ex. E - 05-05-23 Ward - Wyeth initial and AZ counter designations, # 5 Ex. A - 04-26-23 Haber - AZ's Statement of Deposition Transcripts Played at Trial May 14, 2024)(Dellinger, Megan) (Entered: 06/28/2024)
2024-06-28
2
ANSWERING BRIEF in Opposition re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by Wyeth LLC.Reply Brief due date per Local Rules is 7/5/2024. (Attachments: # 1 Ex. A - 04-27-23 Cross - Wyeth initial and AZ counter designations, # 2 Ex. C - 04-25-23 Ghiorghiu - Wyeth initial and AZ counter designations, # 3 Ex. D - 04-12-23 Miller- Wyeth initial and AZ counter designations, # 4 Ex. E - 05-05-23 Ward - Wyeth initial and AZ counter designations, # 5 Ex. A - 04-26-23 Haber - AZ's Statement of Deposition Transcripts Played at Trial May 14, 2024)(Dellinger, Megan) (Entered: 06/28/2024)
2024-06-28
2
ANSWERING BRIEF in Opposition re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by Wyeth LLC.Reply Brief due date per Local Rules is 7/5/2024. (Attachments: # 1 Ex. A - 04-27-23 Cross - Wyeth initial and AZ counter designations, # 2 Ex. C - 04-25-23 Ghiorghiu - Wyeth initial and AZ counter designations, # 3 Ex. D - 04-12-23 Miller- Wyeth initial and AZ counter designations, # 4 Ex. E - 05-05-23 Ward - Wyeth initial and AZ counter designations, # 5 Ex. A - 04-26-23 Haber - AZ's Statement of Deposition Transcripts Played at Trial May 14, 2024)(Dellinger, Megan) (Entered: 06/28/2024)
2024-06-28
2
Exhibit List - Defendants AO 187 Exhibit List by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Keller, Karen) (Entered: 07/01/2024)
2024-07-01
1
Exhibit List -- Joint List of Exhibits Admitted at the Bench Trial -- by Wyeth LLC. (Dellinger, Megan) (Entered: 07/01/2024)
2024-07-01
1
Exhibit List -- Plaintiff's Trial Exhibit List -- by Wyeth LLC. (Dellinger, Megan) (Entered: 07/01/2024)
2024-07-01
1
Exhibit List -- Joint Trial Exhibit List -- by Wyeth LLC. (Dellinger, Megan) (Entered: 07/01/2024)
2024-07-01
1
REDACTED VERSION of 489 Objections, by Wyeth LLC. (Attachments: # 1 Exs. A-E)(Dellinger, Megan) (Entered: 07/02/2024)
2024-07-02
1
REDACTED VERSION of 489 Objections, by Wyeth LLC. (Attachments: # 1 Exs. A-E)(Dellinger, Megan) (Entered: 07/02/2024)
2024-07-02
2
REDACTED VERSION of 494 MOTION Under Rule 59(e) for Supplemental Damages, Interest, and Ongoing Royalties by Wyeth LLC. (Attachments: # 1 Proposed Order)(Dellinger, Megan) (Entered: 07/02/2024)
2024-07-02
1
REDACTED VERSION of 494 MOTION Under Rule 59(e) for Supplemental Damages, Interest, and Ongoing Royalties by Wyeth LLC. (Attachments: # 1 Proposed Order)(Dellinger, Megan) (Entered: 07/02/2024)
2024-07-02
2
REDACTED VERSION of 495 Opening Brief in Support, by Wyeth LLC. (Attachments: # 1 Exs. A-O)(Dellinger, Megan) (Entered: 07/02/2024)
2024-07-02
1
REDACTED VERSION of 495 Opening Brief in Support, by Wyeth LLC. (Attachments: # 1 Exs. A-O)(Dellinger, Megan) (Entered: 07/02/2024)
2024-07-02
2
REDACTED VERSION of 485 Objections,, regarding Deposition Designations for Bench Trial by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 07/02/2024)
2024-07-02
1
Unopposed MOTION to Seal Trial Exhibit PX-018 - filed by Puma Biotechnology, Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Proposed Order)(Dellinger, Megan) (Entered: 07/03/2024)
2024-07-03
1
Unopposed MOTION to Seal Trial Exhibit PX-018 - filed by Puma Biotechnology, Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Proposed Order)(Dellinger, Megan) (Entered: 07/03/2024)
2024-07-03
2
Unopposed MOTION to Seal Trial Exhibit PX-018 - filed by Puma Biotechnology, Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Proposed Order)(Dellinger, Megan) (Entered: 07/03/2024)
2024-07-03
2
Unopposed MOTION to Seal Trial Exhibit PX-018 - filed by Puma Biotechnology, Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Proposed Order)(Dellinger, Megan) (Entered: 07/03/2024)
2024-07-03
2
SO ORDERED, regarding D.I. 507 Unopposed MOTION to Seal Trial Exhibit PX-018. Signed by Judge Matthew F Kennelly on 7/3/2024. (apk) (Entered: 07/03/2024)
2024-07-03
1
REDACTED VERSION of 491 Response to Objections, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 07/03/2024)
2024-07-03
1
SO ORDERED
2024-07-03
1
No Actions
REPLY BRIEF re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 07/05/2024)
2024-07-05
1
REPLY BRIEF re 483 MOTION for Judgment as a Matter of Law [AstraZeneca's Renewed Motion for Judgment as a Matter of Law and Alternative Motion for a New Trial Limited to Invalidity] filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 07/05/2024)
2024-07-05
2
[SEALED] ANSWERING BRIEF in Opposition re 494 MOTION Under Rule 59(e) for Supplemental Damages, Interest, and Ongoing Royalties filed by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP.Reply Brief due date per Local Rules is 7/16/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(DiBenedetto, Emily) (Entered: 07/09/2024)
2024-07-09
1
REDACTED VERSION of 511 Answering Brief in Opposition, by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 07/16/2024)
2024-07-16
1
[SEALED] REPLY BRIEF re 494 MOTION Under Rule 59(e) for Supplemental Damages, Interest, and Ongoing Royalties filed by Wyeth LLC. (Attachments: # 1 Exhibit P, # 2 Exhibit Q, # 3 Exhibit R, # 4 Exhibit S)(Dellinger, Megan) (Entered: 07/16/2024)
2024-07-16
1
REDACTED VERSION of 513 Reply Brief, by Wyeth LLC. (Attachments: # 1 Exs. P-S)(Dellinger, Megan) (Entered: 07/23/2024)
2024-07-23
1
REDACTED VERSION of 513 Reply Brief, by Wyeth LLC. (Attachments: # 1 Exs. P-S)(Dellinger, Megan) (Entered: 07/23/2024)
2024-07-23
2
FINDINGS OF FACT AND CONCLUSIONS OF LAW. Signed by Judge Matthew F Kennelly on 8/6/2024. (jfm) (Entered: 08/06/2024)
2024-08-06
1
Oral Argument
2024-08-08
1
No Actions
1 - Terminate Hearings AND Pretrial Conference AND ~Util - Set Deadlines/Hearings AND ~Util - Set Hearings
2024-08-08
1
No Actions
MEMORANDUM AND ORDER. Signed by Judge Matthew F Kennelly on 8/14/2024. (jfm) (Entered: 08/14/2024)
2024-08-14
1
FINAL JUDGMENT in favor of AstraZeneca AB and AstraZeneca Pharmaceuticals, LP on Counts 1 and 2 of the complaint by Plaintiff Wyeth LLC. Judgment is entered in favor of Wyeth LLC on Counts 1, 3, and 5 of AstraZeneca's Counterclaim. Judgment is entered in favor of AstraZeneca on Counts 2 and 4 of its counterclaim based on a determination that claims 1, 3, and 9 of the '314 patent and claim 1 of the '162 patent are invalid under 35 U.S.C. § 112 for lack of enablement and lack of written description. The non-final judgment entered on May 28, 2024 (dkt. 463 ) is vacated.This is a final and appealable judgment. (CASE CLOSED) Signed by Judge Matthew F Kennelly on 8/14/2024. (mpb) (Entered: 08/14/2024)
2024-08-14
1
FINAL Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,603,314 B2; 10,596,162 B2. (mpb) (Entered: 08/15/2024)
2024-08-14
1
BILL OF COSTS by AstraZeneca AB, AstraZeneca Pharmaceuticals, LP. (DiBenedetto, Emily) (Entered: 08/21/2024)
2024-08-21
1
DECLARATION re 519 Bill of Costs [Declaration of Melissa Keech in Support of AstraZeneca's Bill of Costs] by AstraZeneca AB, AstraZeneca PLC, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Entered: 08/21/2024)
2024-08-21
1
DECLARATION re 519 Bill of Costs [Declaration of Melissa Keech in Support of AstraZeneca's Bill of Costs] by AstraZeneca AB, AstraZeneca PLC, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Entered: 08/21/2024)
2024-08-21
2
DECLARATION re 519 Bill of Costs [Declaration of Melissa Keech in Support of AstraZeneca's Bill of Costs] by AstraZeneca AB, AstraZeneca PLC, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Entered: 08/21/2024)
2024-08-21
2
DECLARATION re 519 Bill of Costs [Declaration of Melissa Keech in Support of AstraZeneca's Bill of Costs] by AstraZeneca AB, AstraZeneca PLC, AstraZeneca Pharmaceuticals, LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(DiBenedetto, Emily) (Entered: 08/21/2024)
2024-08-21
2
OBJECTIONS by Wyeth LLC to 519 Bill of Costs . (Dellinger, Megan) (Entered: 09/04/2024)
2024-09-04
1
NOTICE OF APPEAL to the Federal Circuit of 517 Judgment,, 516 Memorandum and Order . Appeal filed by Wyeth LLC. (Dellinger, Megan) (Entered: 09/12/2024)
2024-09-12
1
- APPEAL - Credit Card Payment (Attorneys Only)
2024-09-12
1
No Actions
USCA Notice of Appeal and Docket Transmitted
2024-09-12
1
No Actions
APPEAL - Credit Card Payment received re 522 Notice of Appeal (Federal Circuit) filed by Wyeth LLC. ( Filing fee $605, receipt number ADEDC-4497024.) (Dellinger, Megan)
2024-09-12
1
No Actions
Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re 522 Notice of Appeal (Federal Circuit). (mpb)
2024-09-12
1
No Actions
NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 522 Notice of Appeal (Federal Circuit) filed by Wyeth LLC. USCA Case Number 24-2325 (jfm) (Entered: 09/17/2024)
2024-09-17
1
NOTICE requesting Clerk to remove Daniele San Roman as co-counsel.. (Dellinger, Megan) (Entered: 06/03/2025)
2025-06-03
1
NOTICE requesting Clerk to remove Meredith A. Stewart as co-counsel.. (Dellinger, Megan) (Entered: 06/03/2025)
2025-06-03
1
MANDATE of USCA as to 522 Notice of Appeal (Federal Circuit) filed by Wyeth LLC. USCA Decision: AFFIRMED. (Attachments: # 1 USCA Judgment, # 2 USCA Opinion)(jfm) (Entered: 08/25/2026)
2026-08-25
1